US China Biopharma Congress 2018
SAPA-GP 16th Annual Conference

Reshaping the Biopharma Ecosystem

June 8 - 9, 2018
Sheraton Valley Forge Hotel
480 N Gulph Rd,
King of Prussia, PA, 19406
Greetings from Conference Co-Chairs

Dear SAPA-GP Members and Friends:

It is our great honor to welcome you to the 2018 Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP) Annual Conference to celebrate our sixteenth year of extraordinary achievements.

In 2017-2018, SAPA-GP under the leadership of the Extended Senior Leadership Team (SLT) and Executive Council (EC) members once again delivered remarkable amounts of extraordinary events and initiatives to enable SAPA-GP to better serve our members and the community. The quantity and quality of our work is truly amazing, as is the passion and determination to achieve results that impact our members and our organization.

One of the key missions of SAPA-GP is to foster and nurture the growth of our young and talented member scientists. The SAPA-GP 2017 Career Development Workshop, led by Dr. Steve Wu, was held at Columbia University in October, 2017. It was entitled: “Jump-start your career, Amazing careers in biopharma”. The workshop attracted attendees from Pennsylvania, Delaware, New York, New Jersey and elsewhere and provided comprehensive information on how to land one's first job and on future career development as well. In addition, under the leadership of Ms. Hao Sun, our widely popular and individually tailored mentor-mentee program continued into its second year's success and doubled the enrollment of mentee-mentor pairs. Dr. Yufeng Li and Dr. Yongchao Su led the first ever SAPA-GP organized two-day advanced pharma R&D training course. It covered the entire pharmaceutical value chain and was presented by prestigious industrial leaders.

To promote in-depth scientific discussion on cutting edge research on cell and gene therapies and bring public awareness of many devastating infectious diseases, championed by Dr. Haifeng Cui and Ms. Hao Sun, we organized a massively successful scientific symposium with the theme of “Break-through Science and Technology in Cell and Gene Therapy”, attended and presented by the most respected scientific leaders from both academia and industry. The symposium was extremely well attended and received positive reviews.

We continued to collaborate with the Inclusion & Diversity Councils and Human Resources of multinational corporations (MNCs) and biotechs in the US and China to help them access the huge talent pool of SAPA-GP. You can check out our frequently updated job postings at SAPA-GP online and explore them in-person at the job fair sessions during this conference.

This year, we are proud to present you a much-expanded conference program with topics ranging from scientific discussion on cutting edge pharmaceutical research and transformational therapies, regulatory environment, drug discovery across US and China, Biologics CMC and vaccine to job fair and career development plan for success. This two-day premier event will be attended by a large number of professionals and provides a perfect platform for you to interact with the field leaders, entrepreneurs, investors, recruiters, human resource specialists, lawyers, government officials, and peers to hear their expert perspectives.

We would like to take this opportunity to thank our leadership team and executive council members for your outstanding contributions. We also would like to express our eternal gratitude towards our sponsors, speakers, volunteers, friends and family members of SAPA-GP for your generosity and support. You made the success of SAPA-GP possible. Together we are shaping up the future of pharmaceutical research and development and making our world healthier! Enjoy the conference.

Zhenhua Wu, Ph.D.
Conference Co-Chair
President, SAPA-GP,
VP, Head of Preclinical Development, United Neuroscience

Han Dai, Ph.D.
Conference Co-Chair
President-Elect, SAPA-GP,
Scientific Leader, GSK Fellow,
GSK
SAPA-GP History

The Greater Philadelphia area is one of the major homes for the world’s pharmaceutical industry. It hosts more than half of the world’s top-ten pharmaceutical companies, and many small/mid-size biotech companies as well as academic institutions. The Sino-American Pharmaceutical Professionals Association - Greater Philadelphia (SAPA-GP) was established in 2002 to serve the rapidly growing pharmaceutical/biotech/healthcare community in the GP area.

SAPA-GP Mission

To promote pharmaceutical sciences and biotechnology
To contribute to public health education by raising public awareness
To facilitate scientific and business cooperation between US and China
To foster career development of pharmaceutical professionals

2017~2018 SAPA-GP Events & Achievements

2017/08/07  Webinar “Global Impact of Regulatory Overhaul in China”: Co-organized with FMD K&L and presented by Dr. Simon Li & Dr. Dan Zhang.
2017/08/17  Representatives from the Department of Commerce of Hubei Province visited Philadelphia & New York City and signed collaboration agreement with SAPA-GP.
2017/08/23  Nanjing Biotech and Pharmaceutical Valley Leadership team visited SAPA-GP and met with SAPA-GP SLT, entrepreneurs and more than 40 experts from greater Philadelphia area.
2017/10/01  Career Development Workshop for postdoctoral fellows and graduate students was held at Columbia University.
2017/10/21  Twenty-five trainees received graduation certificate from 1st SAPA-GP Advanced Course on Pharmaceutical R&D.
2017/12/15  Philadelphia Pharmaceutical Symposium “Cell and Gene Therapy” attracted more than 200 attendees from academia, biotech, and pharmaceutical companies.
2018/04/06  2018 SAPA-GP Mentor-Mentee Program started to receive applications.
2018/05/26  SAPA-GP Summer Picnic at Peace Valley Park, PA.
2018/06/08  SAPA-GP 16th Annual Conference at Sheraton Valley Forge Hotel at King of Prussia, PA.
### Conference at-a-Glance

**8:25 - 8:30 AM**  
Opening Speech  
Grand Ballroom

**8:30 - 8:50 AM**  
Presidential Election Speech  
Grand Ballroom

**8:50 - 10:20 AM**  
Plenary Session:  
Making Greater Philadelphia a Vibrant Hub for Life Science Startup Ventures  
Grand Ballroom

### 10:30 AM - 12:00 PM Morning Sessions I - V

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Grand Ballroom</td>
<td>Centennial Ballroom I</td>
<td>Centennial Ballroom II</td>
<td>Centennial Ballroom III</td>
<td>Haverford</td>
</tr>
</tbody>
</table>

### 12:30 PM - 1:30 PM Lunch Sessions A - D

<table>
<thead>
<tr>
<th>Lunch Session A: Solutions for Your Long-Term Income Needs</th>
<th>Lunch Session B: The Cultural and Legal Challenges for Chinese Companies Conducting Acquisition or Investment Deals in the US</th>
<th>Lunch Session C: Operational Risk Management for Life Science Companies - Risk, Protection and Loss Control</th>
<th>Lunch Session D: How Do Big Data Analytics Application and Visualization Change the Landscape of US Pharma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ardmore</td>
<td>Haverford</td>
<td>Malvern</td>
<td>Paoli</td>
</tr>
</tbody>
</table>

### 1:30 PM - 5:00 PM Afternoon Sessions III, and VI - X

<table>
<thead>
<tr>
<th>1:30 - 3:30 PM</th>
<th>Session VI: Biologics CMC and Vaccine: Delivering the Excellence of Biopharmaceutical Medicines to Patients</th>
<th>1:30 - 2:30 PM</th>
<th>Session III (afternoon): Neuroscience Touchdowns: Scientific Advances to Tackle Devastating Neurological Disease</th>
<th>1:30 - 4:30 PM</th>
<th>Session IX: CEO Forum</th>
<th>1:30 - 5:00 PM</th>
<th>Session X: Job Fair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grand Ballroom</td>
<td>Centennial Ballroom I</td>
<td>Centennial Ballroom II</td>
<td>Centennial Ballroom III</td>
<td>Centennial Ballroom III</td>
<td>Frazer, Gladwyne, Devon, Bryn Mawr</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1:30 - 5:00 PM</th>
<th>Session VII: Money Meets Ideas: Alpha Bioventure-Liberty Bell Venture Forum</th>
<th>2:30 - 5:00 PM</th>
<th>Session VIII: Career Development: Reinvent yourself</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centennial Ballroom I</td>
<td></td>
<td>Centennial Ballroom II</td>
<td>Centennial Ballroom II</td>
</tr>
</tbody>
</table>

---

**Exit**  
**Restroom**

- Executive Boardroom  
- St. Davids  
- Centennial Ballroom III  
- Malvern  
- Haverford  
- Centennial Ballroom II  
- Centennial Ballroom I  
- Grand Ballroom  
- Hotel Lobby  
- Main Entrance  
- Gladwyne  
- Paoli  
- Bryn Mawr  
- Berwyn  
- Stratford  
- Ardmore  
- Devon  
- Stradford
AGENDA  June 8th, Friday

8:00-8:25 a.m.  Check in
8:25-8:30 a.m.  Opening Speech
8:30-8:50 a.m.  Presidential Election Speech

Plenary Session  Making Greater Philadelphia a Vibrant Hub for Life Science Startup Ventures
Session chairs: Jing Yang, Ph.D. Senior Principal Scientist, Cardiovascular Discovery Biology, BMS
Patrick Deng, M.B.A. Finance Director, Johnson & Johnson
Dennis Gross, Ph.D. CEO and Treasurer, Pennsylvania Drug Discovery Institute

8:50-9:10 a.m.  Christopher P. Molineaux, B.A. President & CEO, Life Sciences Pennsylvania
Making Greater Philadelphia a Vibrant Hub for Life Science Startup Ventures

9:10-9:30 a.m.  Steve Q. Yang, Ph.D. EVP, CBO & CSO, WuXi AppTec
Innovation Platform, Network and Ecosystem

9:30-10:20 a.m.  Christopher P. Molineaux, B.A. President & CEO, Life Sciences Pennsylvania
Biao Zheng, M.D., Ph.D. CSO, GenFleet Therapeutics
Drug Discovery and Innovation in China: from a Regional Perspective and Beyond
Alfred Saah, M.D. Executive Director in the Global Center for Scientific Affairs, Merck&Co.
Cervical Cancer Prevention for China: The Path to Gardasil Licensure
Dajun Yang, M.D., Ph.D. Chairman & CEO, Ascentage Pharma Group Corporation, Ltd.
Strategy and Challenges for Global Innovative Drugs
Panel Discussion
Hugh M. Davis, Ph.D. CBO, Frontage Laboratories, Inc.
James Fendrick, B.S. President & CEO, Rockland Immunochemicals, Inc.
Dennis Gross, Ph.D. CEO and Treasurer, Pennsylvania Drug Discovery Institute
Frank Li, Ph.D. President, Alliance Pharma
Christopher P. Molineaux, B.A. President & CEO, Life Sciences Pennsylvania
Lauren Schwartz, B.A. Senior Director, International Business, Department of Commerce, City of Philadelphia
Steve Q. Yang, Ph.D. EVP, CBO & CSO, WuXi AppTec

Session I  Drug Discovery Across US and China
Session chairs: Zhiyun Wen, M.S. Sr. Scientist, Merck&Co.
Hanghang Zhang, Ph.D. Fels Institute of Cancer Research, Temple University

10:30-11:00 a.m.  Biao Zheng, M.D., Ph.D. CSO, GenFleet Therapeutics
Drug Discovery and Innovation in China: from a Regional Perspective and Beyond

11:00-11:30 a.m.  Alfred Saah, M.D. Executive Director in the Global Center for Scientific Affairs, Merck&Co.
Cervical Cancer Prevention for China: The Path to Gardasil Licensure

11:30-12:00 p.m.  Dajun Yang, M.D., Ph.D. Chairman & CEO, Ascentage Pharma Group Corporation, Ltd.
Strategy and Challenges for Global Innovative Drugs

Session II  Regulatory, Clinical & Safety Considerations for the Approval of Cell and Gene Therapy Products

Centennial Ballroom I
Session chairs: Jim Wang, Ph.D., M.B.A. Head of Regulatory Affairs Strategy, Spark Therapeutics
Dan He, Ph.D. Drexel University, Department of Biology

10:30-11:00 a.m.  Jim Wang, Ph.D., M.B.A. Head of Regulatory Affairs Strategy, Spark Therapeutics
Regulatory Review and Approval for Luxturna (voretigene neparvovec-rzyl), the First FDA Approved Gene Therapy Treating a Genetic Disease

11:00-11:30 a.m.  Daniel C. Chung, D.O., M.A. Clinical Ophthalmic Lead, Spark Therapeutics
Luxturna (voretigene neparvovec-rzyl), the First FDA Approved Gene Therapy for a Genetic Disease, A Treatment Option for Patients with Biallelic RPE65 Mutation-Associated Retinal Dystrophy and Viable Retinal Cells

11:30-12:00 p.m.  Weiguo Dai, Ph.D. Scientific Director, Janssen Fellow, Johnson & Johnson
CAR-T Cell Drug Product Manufacturing Challenges and Opportunities
Session III  **Neuroscience Touchdowns: Scientific Advances to Tackle Devastating Neurological Disease**  
Centennial Ballroom II  
Session chairs: Zhenhua Wu, Ph.D. President, SAPA-GP, VP, Head of Preclinical Development, United Neuroscience  
David Cragin, Ph.D. Associate Director, Merck & Co.  
10:30-11:00 a.m.  
Min Li, Ph.D. SVP, Head of Neuroscience R&D, GSK  
*Neuroscience Therapeutics through the 2020 Lens*  
Gong Chen, Ph.D. Professor and Verne M. Willaman Chair in Life Sciences, Penn State University  
*A Novel Gene Therapy for Stroke: In Situ Astrocyte-to-Neuron Conversion*  
Jason Uslaner, Ph.D. Executive Director of Neuroscience, Pain and Symptomatics, Merck & Co.  
*Identifying the Bullseye from the Bull: Selecting Neuroscience Targets to Invest In*  
1:30-2:00 p.m.  
Ian J. Reynolds, Ph.D. VP of Discovery Research, Teva Pharmaceuticals  
*Slowing Neurodegeneration: Progresses and Pitfalls*  
Eric Karran, Ph.D. VP of Foundational Neuroscience Center, AbbVie Neuroscience, AbbVie  
*What does Recent Clinical Data Tell Us about the Amyloid Cascade Hypothesis?*  

Session IV  **Artificial Intelligence-Powered Drug Discovery**  
Centennial Ballroom III  
Session chairs: Fang Shen, Ph.D. Principal Scientist, Janssen R&D  
Xianhua Li, Ph.D. Villanova University, Department of Chemical Engineering  
10:30-11:00 a.m.  
John M. Baldoni, Ph.D. SVP, In Silico Discovery/Proof of Concept, GSK  
*Integrating AI Driven Workflows in Pharma Drug Discovery*  
Alex Zhavoronkov, Ph.D. CEO, Insilico Medicine, Inc., CSO, the Biogerontology Research Foundation  
*Comprehensive End-to-End AI-powered Drug Discovery Pipelines*  
Jie Fan, Ph.D. Founder, Accutar Biotech  
*Artificial Intelligence Solutions to Drug Discovery—from Virtual Screen to Drug ADME Prediction*  

Session V  **Leveraging Real World Evidence to Transform Drug Development**  
Haverford  
Session chairs: Jun Xing, Ph.D. Senior Associate Director, BMS  
Shuang “Steve” Wu, Ph.D. Consulting Associate, Life Sciences Practice, Charles River Associates  
Di Wu, Ph.D. Candidate, School of Pharmacy, Temple University  
10:30-11:00 a.m.  
Xianchen Liu, M.D., Ph.D. Senior Medical Director, Pfizer  
*Real-world Data in the Digital Era*  
Danyi Wen, M.D., M.B.A. President & CEO, Shanghai LIDE Biotech Co., Ltd  
*Functional Diagnostics and RWE*  
Andres Gomez, Ph.D. VP, Head of Epidemiology, Safety Science and Analytics Team, BMS  
*Use of RWE for Safety Signal Detection: Is There More We Can Do?*  
12:30-1:30 p.m.  
*Lunch Session*  

Lunch session A  
Solutions for Your Long-Term Income Needs  
Carolyn Choh, M.B.A. Investment Adviser Representative, Financial Independence Planning, LLC.  
Session chair: Yutai Li, Ph.D. Principal Scientist, Merck & Co.  

Lunch session B  
The Cultural and Legal Challenges for Chinese Companies Conducting Acquisition or Investment Deals in the US  
Zhiping Liu, J.D. Partner, Liu, Zheng, Chen & Hoffman LLP  
Session chair: Yeqing Tao, Ph.D. Investigator, GSK  

Lunch session C  
Operational Risk Management for Life Science Companies-Risk, Protection and Loss Control  
Tracy Xu, M.B.A. Area Vice President, Arthur J. Gallagher Inc.  
Walker Taylor IV, B.S. Life Sciences Team Niche Leader, Arthur J. Gallagher Inc.  
Session chair: Pengbo Guo, Ph.D. Candidate, Temple University, School of Pharmacy  

Lunch session D  
How Do Big Data Analytics Application and Visualization Change the Landscape of US Pharma  
Ning Jia, M.S. Associate Principal, KMK Consulting Inc.  
Huanxue Zhou, M.S. Director of Health Economics & Outcomes Research, KMK Consulting, Inc.  
Session chair: Hao Wu, Ph.D. Technical Specialist, Howson & Howson, LLP
Session VI Biologics CMC and Vaccine: Delivering the Excellence of Biopharmaceutical Medicines to Patients

Session chairs: Yongchao Su, Ph.D. Associate Principal Scientist, Merck & Co.
        Lu Wang, Ph.D. Senior Scientist, Teva Pharmaceuticals
1:30-2:00 p.m. Jason Bock, Ph.D. VP of Global CMC Biologics, Teva Pharmaceuticals
        Achieving Efficiency through a Comprehensive Approach to Organization, Facility and Process
2:00-2:30 p.m. Allen Templeton, Ph.D. VP of Pharmaceutical Science, Merck & Co.
        Contemporary Themes in Bioformulation Research: Philosophy, Biophysics and Analytics
2:30-3:00 p.m. Le Sun, Ph.D. President & CEO, AbMax Biotechnology Co., Ltd.
        De-immunogenicity and Humanization of Antibody Drugs
3:00-3:30 p.m. Pengchong Wei, M.S. Founder & CEO, Beijing Simoon Record Pharma Information Consulting Co., Ltd.
        Vaccine Clinical Study in China

Session VII Money Meets Ideas: Alpha Bioventure-Liberty Bell Venture Forum

Session chairs: Han Dai, Ph.D. President-Elect, SAPA-GP, Scientific Leader, GSK Fellow, GSK
        Yang Liu, Ph.D. Investigator, GSK
1:30-1:35 p.m. Opening Remarks
        Han Dai, Ph.D. President-Elect, SAPA-GP, Scientific Leader, GSK Fellow, GSK
1:35-1:40 p.m. Bo Liang, Ph.D. Managing Director, Alpha Bioventure LLC; President of IVIEW Therapeutics Inc.
        Alpha Bioventure: Promoting Early Stage Life Science Innovations
1:40-1:55 p.m. Brad Loncar, B.A. CEO, Loncar Investments
        The Biotech Landscape in the US and China
1:55-2:10 p.m. Kechun Li, M.S., M.B.A. Managing Partner, Yuanmin Capital
        Life Science Boom Driven by Capital, Talents and New Policy
2:10-3:50 p.m. Road Show
3:50-4:00 p.m. Award Ceremony
4:00-4:25 p.m. Panel Discussion
4:25-4:30 p.m. Closing Remarks
        Yang Liu, Ph.D. Investigator, GSK
4:30-5:00 p.m. After-session Discussion
        Session chair: Donghui Li, Ph.D. Venture Associate, Alpha Bioventure

Session VIII Career Development: Reinvent yourself

Session chairs: Chun Shao, Ph.D. Investigator, GSK
        Huaping Tang, Ph.D. Principal Scientist, Merck & Co.
3:00-3:30 p.m. Eric Duan, B.A. VP, Beijing Career International Co., Ltd
        Boom Healthcare Job Market in China
3:30-4:00 p.m. Andrea McIntire, M.S. Human Resources Manager and Professional Coach, GSK
        Creating a Meaningful Career
4:00-4:30 p.m. Jane Li, B.S. Co-founder, ArcaneFire Recruiting Co., Ltd
        Landscape of Healthcare Job Market in China
4:30-5:00 p.m. Fang Shen, Ph.D. Principal Scientist, Janssen R&D
        How to Make the Most Out of Mentorship: A Guide To Mentee
Session IX CEO Forum
Session chairs: Li Yan, Ph.D. Member of the Board, MATWIN, Adjunct Professor, Yonsei University
Xue Liang, Ph.D. Microbiome Scientist, Merck Exploratory Science Center, Merck & Co.
1:30-4:30 p.m. Panel discussion
  Dahai Guo, M.S., M.B.A. Founder & CEO, PuraCap Pharmaceutical LLC.
  Sean X. Hu, Ph.D. M.B.A. CEO, Avotres Inc. (USA)
  Zak Huang, M.D. Head, China R&D, CSL Behring
  Frank Li, Ph.D. President, Alliance Pharma
  Simon Li, M.D., Ph.D. Chief Medical Officer, VP of CSPC Pharma
  Song Li, Ph.D. Founder & CEO, Frontage Laboratories, Inc.
  Bill Liang, Ph.D., M.B.A. Co-founder, CF PharmTech., Inc.
  Peter (Peizhi) Luo, Ph.D. Founder & CEO, Adagene
  Jie Sly, Ph.D., M.B.A. VP, Corporate Development and Innovation Lab Operations, ACROBiosystems
  Danyi Wen, M.D., M.B.A. President & CEO, Shanghai LIDE Biotech Co., Ltd
  Gilbert Wen, Ph.D. Founder, Overseas Pharmaceuticals, Ltd.
  Dajun Yang, M.D., Ph.D. Chairman & CEO, Ascentage Pharma Group Corporation, Ltd.
  Sean Zhang, M.D. CEO, Hengrui Therapeutics, Inc.
  Biao Zheng, M.D., Ph.D. CSO, GenFleet Therapeutics
  Demin Zhu, Ph.D. President & CEO, Curelong Group

Session X Job Fair 1:30-5:00 p.m.
Session chairs: Hui Wang, Ph.D. Director of Business Development, Klus Pharma
  Hao Sun, M.S. Senior Scientist, GSK
  Hao Wu, Ph.D. Technical Specialist, Howson & Howson, LLP

Gala Dinner (By Invitation Only)
Gala hosts: Jing Yang, Ph.D. Senior Principal Scientist, Cardiovascular Discovery Biology, BMS
  Fang Shen, Ph.D. Principal Scientist, Janssen R&D
6:00-6:30 p.m. Guest Presentation
  Jijun Xing, Ph.D., Science and Technology Counselor, Chinese Consulate-General in New York
6:30-6:45 p.m. Year-end Remarks
  Zhenhua Wu, Ph.D. President, SAPA-GP, VP, Head of Preclinical Development at United Neuroscience
6:45-6:50 p.m. SAPA-GP 2018-2019 Plan and Presidential Election Result
  Han Dai, Ph.D. President-Elect, SAPA-GP, Scientific Leader, GSK Fellow, GSK
6:50-7:00 p.m. Volunteer of the Year Nomination
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-8:55</td>
<td>Parking, Registration and Morning Coffee</td>
<td></td>
</tr>
<tr>
<td>8:55-9:00</td>
<td>Yufeng Li</td>
<td>Opening Remark</td>
</tr>
<tr>
<td>8:55-9:00</td>
<td>Yufeng Li</td>
<td>Opening Remark</td>
</tr>
<tr>
<td>8:55-9:00</td>
<td>Yufeng Li</td>
<td>Opening Remark</td>
</tr>
<tr>
<td>9:00-10:00</td>
<td>Haifeng Cui</td>
<td>Preclinical Discovery</td>
</tr>
<tr>
<td>9:00-10:00</td>
<td>Haifeng Cui</td>
<td>Preclinical Discovery</td>
</tr>
<tr>
<td>9:00-10:00</td>
<td>Haifeng Cui</td>
<td>Preclinical Discovery</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>Jason Huang</td>
<td>Clinical Development</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>Jason Huang</td>
<td>Clinical Development</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>Jason Huang</td>
<td>Clinical Development</td>
</tr>
<tr>
<td>11:00-11:15</td>
<td>Charles Wang</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:15-12:00</td>
<td>Charles Wang</td>
<td>Nonclinical Safety Evaluation in Drug Development</td>
</tr>
<tr>
<td>11:15-12:00</td>
<td>Charles Wang</td>
<td>Nonclinical Safety Evaluation in Drug Development</td>
</tr>
<tr>
<td>11:15-12:00</td>
<td>Charles Wang</td>
<td>Nonclinical Safety Evaluation in Drug Development</td>
</tr>
<tr>
<td>12:00-13:15</td>
<td>Jingtao Zhang</td>
<td>Lunch</td>
</tr>
<tr>
<td>12:00-13:15</td>
<td>Jingtao Zhang</td>
<td>Lunch</td>
</tr>
<tr>
<td>12:00-13:15</td>
<td>Jingtao Zhang</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:15-14:00</td>
<td>Jingtao Zhang</td>
<td>Introduction to Dosage Form Development and Drug Delivery</td>
</tr>
<tr>
<td>13:15-14:00</td>
<td>Jingtao Zhang</td>
<td>Introduction to Dosage Form Development and Drug Delivery</td>
</tr>
<tr>
<td>13:15-14:00</td>
<td>Jingtao Zhang</td>
<td>Introduction to Dosage Form Development and Drug Delivery</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Patrick Liu</td>
<td>Biologics</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Patrick Liu</td>
<td>Biologics</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Patrick Liu</td>
<td>Biologics</td>
</tr>
<tr>
<td>15:00-15:15</td>
<td>Jim Wang</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:15-16:00</td>
<td>Jim Wang</td>
<td>Regulatory Strategy</td>
</tr>
<tr>
<td>15:15-16:00</td>
<td>Jim Wang</td>
<td>Regulatory Strategy</td>
</tr>
<tr>
<td>15:15-16:00</td>
<td>Jim Wang</td>
<td>Regulatory Strategy</td>
</tr>
<tr>
<td>16:00-17:00</td>
<td>Lihua Zheng</td>
<td>Trends in IP Transactions</td>
</tr>
<tr>
<td>16:00-17:00</td>
<td>Lihua Zheng</td>
<td>Trends in IP Transactions</td>
</tr>
<tr>
<td>16:00-17:00</td>
<td>Lihua Zheng</td>
<td>Trends in IP Transactions</td>
</tr>
<tr>
<td>17:00-17:05</td>
<td>Yongchao Su</td>
<td>Closing Remark</td>
</tr>
<tr>
<td>17:00-17:05</td>
<td>Yongchao Su</td>
<td>Closing Remark</td>
</tr>
<tr>
<td>17:00-17:05</td>
<td>Yongchao Su</td>
<td>Closing Remark</td>
</tr>
<tr>
<td>17:05-17:30</td>
<td>Yongchao Su</td>
<td>Networking, Group Photo</td>
</tr>
<tr>
<td>17:05-17:30</td>
<td>Yongchao Su</td>
<td>Networking, Group Photo</td>
</tr>
<tr>
<td>17:05-17:30</td>
<td>Yongchao Su</td>
<td>Networking, Group Photo</td>
</tr>
</tbody>
</table>
# Pharma R&D Executive Forum

**Current frontiers and future perspectives on multiple disease areas**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-8:55</td>
<td>Parking, Registration and Morning Coffee</td>
<td></td>
</tr>
<tr>
<td>8:55-9:00</td>
<td>Zhenhua Wu</td>
<td>Opening Remark</td>
</tr>
<tr>
<td></td>
<td>President</td>
<td>SAPA-GP</td>
</tr>
<tr>
<td>9:00-10:00</td>
<td>Zhenhua Wu</td>
<td>Neuro</td>
</tr>
<tr>
<td></td>
<td>VP of Discovery</td>
<td>United Neuroscience</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>Han Dai</td>
<td>Oncology</td>
</tr>
<tr>
<td></td>
<td>Scientific Leader</td>
<td>GSK</td>
</tr>
<tr>
<td>11:00-11:15</td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:15-12:15</td>
<td>Jing Yang</td>
<td>Cardiovascular Perspectives on the New Era of Cardiovascular Disease Prevention and Treatment</td>
</tr>
<tr>
<td></td>
<td>Senior Principal Scientist</td>
<td>BMS</td>
</tr>
<tr>
<td>12:15-13:30</td>
<td></td>
<td>Lunch</td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Haifeng Cui</td>
<td>Infectious Disease</td>
</tr>
<tr>
<td></td>
<td>Scientific Director</td>
<td>GSK</td>
</tr>
<tr>
<td>14:30-15:30</td>
<td>Fang Shen</td>
<td>Immunology</td>
</tr>
<tr>
<td></td>
<td>Principal Scientist</td>
<td>Jassen R&amp;D</td>
</tr>
<tr>
<td>15:30-15:35</td>
<td>Fang Shen</td>
<td>Closing Remark</td>
</tr>
<tr>
<td></td>
<td>VP</td>
<td>SAPA-GP</td>
</tr>
<tr>
<td>15:35-16:00</td>
<td></td>
<td>Networking, Group Photo</td>
</tr>
</tbody>
</table>
forms of migraine. Cinqair™ is the first commercially approved
Chen pioneered an innovative
cell conversion technology for
Dr. Chen is Willaman Chair Professor at Penn State University. Dr.
the discovery and manufacture of small molecules,
biopharmaceuticals, and cell and gene therapies. John joined GSK in
1989 and has worked in the pharmaceutical industry for 37 years.
His experience spans new chemical entity design, development and
and commercialization, and biopharmaceutical development. In
progressing to his current role, John has held various positions at
GSK including Senior Vice President, Preclinical Development; Vice
President, Product Development; Director, Product Development;
and Assistant Director, Biopharmaceutical Formulation
Development, among others. He has led several key cross-functional
strategic initiatives, such as advanced manufacturing technologies
and discovery modernization. John has a B.S. degree in biochemistry
(1974), and MS and Ph.D. degrees in chemistry (1980) from Penn
State University.

SPEAKERS

John M. Baldoni, Ph.D.
SVP, In Silico Discovery/Proof of Concept,
GSK

John Baldoni is Senior Vice President, In silico Drug Discovery, in
GSK Pharma R&D. This department will use in silico methods to
identify patient needs, explore molecular interventions to address
those needs and design and conduct clinical trials to test the medical
hypothesis. These methodologies will reduce test cycle, increase
precision and lower cost. Prior to this, John was Senior Vice
President, Platform Technology and Science (PTS), in GSK. The
work of PTS spans the entire drug discovery and development
process, from preclinical activities leading to clinical candidate
selection through commercial launch. This accountability covered
the discovery and manufacture of small molecules,
biopharmaceuticals, and cell and gene therapies. John joined GSK in
1989 and has worked in the pharmaceutical industry for 37 years.
His experience spans new chemical entity design, development and
and commercialization, and biopharmaceutical development. In
progressing to his current role, John has held various positions at
GSK including Senior Vice President, Preclinical Development; Vice
President, Product Development; Director, Product Development;
and Assistant Director, Biopharmaceutical Formulation
Development, among others. He has led several key cross-functional
strategic initiatives, such as advanced manufacturing technologies
and discovery modernization. John has a B.S. degree in biochemistry
(1974), and MS and Ph.D. degrees in chemistry (1980) from Penn
State University.

Jason Bock, Ph.D.
VP of Global CMC Biologics, Teva
Pharmaceuticals

Jason Bock, PhD, is currently Vice President of Biologics CMC at
Teva Pharmaceuticals, Specialty R&D Division. Over the last 10
years, Dr. Bock has worked to establish advanced end-to-end
biologics capabilities to drive Teva’s Specialty R&D portfolio. Dr.
Bock leads and oversees the Specialty R&D site in West Chester,
Pennsylvania. He is directly accountable for all aspects of biologics
CMC development and manufacturing from initial preclinical
toxicity, clinical development, commercialization preparation
through BLA filing. Under his guidance, Teva Specialty R&D has
filed 3 BLAs for innovative Biologics in the last 4 years including
Cinqair® for severe forms of asthma and fremanezumab for severe
forms of migraine. Cinqair® is the first commercially approved
monoclonal antibody in the Teva portfolio. Dr. Bock joined Teva
through the acquisition of CoGenesys, a private biotech company
founded as a spinoff from Human Genome Sciences (HGS). Prior to
founding CoGenesys, he held positions in the Process Development
and Lead Development and Characterization groups at HGS. Dr.
Bock received his Bachelor’s degree in Biology from MIT and his
Ph.D. in Molecular and Cellular Physiology from Stanford
University. He has an extensive publication record, including several
articles in Nature.

Gong Chen, Ph.D.
Professor and Verne M. Willaman Chair in
Life Sciences, Penn State University

Dr. Chen is Willaman Chair Professor at Penn State University. Dr.
Chen pioneered an innovative in situ cell conversion technology for
brain and spinal cord repair. Unlike traditional stem cell
transplantation therapy, Dr. Chen and his team make use of brain
internal glial cells that normally surround neurons to regenerate new
neurons in situ. Because glial cells are residential cells throughout
the brain and spinal cord, Dr. Chen’s technology opens a new field
that can essentially treat a wide range of neurological disorders,
including traumatic brain injury, stroke, Alzheimer’s disease,
Parkinson’s disease, spinal cord injury, and ALS, through gene
therapy or drug therapy. Chen’s breakthrough findings have been
widely reported in the news media, kindling new hope for millions of
patients around the world. To translate his new technology from
bench to the bedside, Dr. Chen and team members have filed and
obtained a series of patent applications. Dr. Chen is a founder of
NeuExcel Therapeutics Inc., a company aiming to lead a revolution
in brain and spinal cord repair by transforming his cutting-edge
technologies into therapeutic treatments to save millions of lives.
Professor Chen is a member of many professional societies, and
honored by the Alzheimer's Association with Zenith Fellows Award.
Dr. Chen has published many scientific papers in high-impact
journals such as Cell Stem Cell, Nature Communications, Nature,
Cell, FNAS, and received funding from NH, NSF, AHA, etc. Dr.
Chen has presented invited talks and keynote speeches at many
international conferences and leading institutions. Dr. Chen
organized and Chaired the first symposium in history on in vivo cell
conversion in the CNS at the 2014 annual meeting of Society for
Neuroscience in Washington DC. This symposium is a milestone
marking a new field of in vivo cell conversion in regenerative medicine.

Carolyn Choh, M.B.A.
Investment Adviser Representative, Financial
Independence Planning, LLC.

Carolyn Choh, M.B.A. is an Investment Adviser Representative with
Financial Independence Planning, LLC.
After graduation, Carolyn joined the pharmaceutical industry where
she held increasing responsibility in sales and marketing. Carolyn
was a global product director at Wyeth and later Vice President at
Saatchi & Saatchi. She transitioned her experience into teaching
pharmaceutical marketing and was a professor at Saint Joseph’s
University for over 10 years prior to joining the FIP team. Carolyn is
committed to the importance of life-long education. Carolyn has
conducted financial education seminars focused on the topics of
financial planning around life events: “What to do When a Loved
one or Spouse Passes” and “6 Steps when Faced with a Corporate or
Life Transition”. She also runs a series of afternoon tea/workshops
for women, “Financial ABCs for Women”. Carolyn is a registered
investment adviser representative with Voya Financial Advisors and
has the series 7 and 66 securities registrations. She also has Life,
Health and Disability insurance licenses with the State of PA.
Carolyn has her B.A. in Biochemistry/Asian Studies and M.B.A.
from Cornell University.

Daniel C. Chung, D.O., M.A.
Clinical Ophthalmic Lead, Spark Therapeutics

Dr. Chung is the Ophthalmology Lead for Clinical Development and
Clinical R and D at Spark Therapeutics and the company’s inherited
retinal disease resource. He also served as Spark’s Medical Affairs
Ophthalmic Lead. In his current role, he works in the areas of
clinical development and operations, marketing, commercial, patient
advocacy, pre-clinical research and development and business
development. Prior to joining Spark Therapeutics, he was a senior investigator/instructor at the FM Kirby Center for Molecular Ophthalmology at the Scheie Eye Institute at the Perelman School of Medicine of the University of Pennsylvania, working in retinal gene transfer and therapy. Concurrently, he served as the scientific advisor on the RPE65 gene therapy study team for phase 1 and 3 of the clinical trial at the Children’s Hospital of Philadelphia (CHOP). He was the lead designer of the Phase 3 MLMT novel endpoint, PI of the MLMT study, and PI of the RPE65 Natural History Study. He completed his ophthalmology residency in Akron, Ohio. He then completed fellowships in pediatric ophthalmology and ocular genetics research at the Cole Eye Institute at the Cleveland Clinic, and in retinal gene therapy at the National Eye Institute/NIH in Bethesda, MD.

Dr. Han Dai is currently a Scientific Leader and GSK Fellow at GSK. He joined GSK in 2019 as the Lead Principal Scientist for Ocular Gene Therapy before being promoted to Scientific Director in 2021. Prior to joining GSK, Dr. Dai was a Senior Scientist at Spark Therapeutics, where he led the program development and team management of a Phase 1/2/3 clinical trial at the Children’s Hospital of Philadelphia (CHOP). He is a member of the American Society for Ophthalmic Investigative Research (ASOIR) and the American Society for Biochemistry and Molecular Biology (ASBMB) and has published more than 40 papers, book chapter, abstracts and patents in reputable journals and conference proceedings.

Dr. Dai earned his Ph.D. degree from The Johns Hopkins University in 1996, and has over 20 years of US industrial working experience in biotech/pharmaceutical companies, including Amgen, and Johnson and Johnson.

Dr. Weiguo Dai is a Scientific Director in Biological Drug Product Development at Janssen/Johnson & Johnson where he has served as Vice President and Head of Biologics Development Sciences in the Janssen BioTherapeutics & Johnson (JBIO) division of Janssen R&D, LLC since 2001. JBIO is responsible for creating and characterizing all biologic assets for J&J, across all therapeutic areas. In this role, Hugh participated in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvert®, Durzales® and Tremfya®. Prior to J&J, Hugh led the Pharmacodynamics & Exploratory Research Laboratory in the Clinical Pharmacology Unit at GlaxoSmithKline from 1996 to 2001. Hugh has published over 75 manuscripts in refereed journals, book chapters and invited review articles in areas of therapeutic drug discovery, clinical pharmacology and development in immunology, oncology, metabolic disease, bone metabolism and cardiovascular medicine. Following receipt of his Bachelor’s degree in Chemistry from Gannon University in 1980 and Master’s and Doctorate degrees in Biochemistry from Villanova University in 1983 and 1985, Hugh completed a Post-Doctoral Fellowship at Centocor, Inc. where he patented the characterization of the CA 125 cancer antigen, a marker used in the diagnosis of ovarian cancer. Hugh has taught Chemistry, Biochemistry and Physics at Delaware County Community College, Immaculata University, Thomas Jefferson University and for 30 years at Villanova University, primarily teaching Allied Health majors in General, Biochemistry and Organic Chemistry. Hugh is a member of the Villanova University College of Liberal Arts and Sciences Dean’s Advisory Council.

Hugh M. Davis, Ph.D.
CBO, Frontage Laboratories, Inc.

Hugh M. Davis, Ph.D. is the Chief Business Officer (CBO), in charge of Business Development, Sales, Marketing and Strategic Partnerships for Frontage Laboratories, Inc. In addition, Hugh is President of the therapeutics division of Frontida BioPharm. In this capacity, he has responsibility for developing risk-shared, equity investment partnerships and joint ventures with biopharmaceutical companies to build a portfolio of therapeutic assets and platforms for Frontida BioPharm. Hugh has over 30 years of experience in the pharmaceutical industry. His most recent position was with Johnson & Johnson where he has served as Vice President and Head of Biologics Development Sciences in the Janssen BioTherapeutics (JBIO) division of Janssen R&D, LLC since 2001. JBIO is responsible for creating and characterizing all biologic assets for J&J, across all therapeutic areas. In this role, Hugh participated in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvert®, Durzales® and Tremfya®. Prior to J&J, Hugh led the Pharmacodynamics & Exploratory Research Laboratory in the Clinical Pharmacology Unit at GlaxoSmithKline from 1996 to 2001. Hugh has published over 75 manuscripts in refereed journals, book chapters and invited review articles in areas of therapeutic drug discovery, clinical pharmacology and development in immunology, oncology, metabolic disease, bone metabolism and cardiovascular medicine. Following receipt of his Bachelor’s degree in Chemistry from Gannon University in 1980 and Master’s and Doctorate degrees in Biochemistry from Villanova University in 1983 and 1985, Hugh completed a Post-Doctoral Fellowship at Centocor, Inc. where he patented the characterization of the CA 125 cancer antigen, a marker used in the diagnosis of ovarian cancer. Hugh has taught Chemistry, Biochemistry and Physics at Delaware County Community College, Immaculata University, Thomas Jefferson University and for 30 years at Villanova University, primarily teaching Allied Health majors in General, Biochemistry and Organic Chemistry. Hugh is a member of the Villanova University College of Liberal Arts and Sciences Dean’s Advisory Council.

Dr. Weiguo Dai is a Scientific Director in Biological Drug Product Development at Janssen/Johnson & Johnson. Dr. Dai’s scientific and industrial impact has been reflected by his election into the Inaugural Janssen Fellow Community (globally total of 62) in 2012 and as the Fellow of American Association of Pharmaceutical Scientists (AAPhS) in 2013. Dr. Dai is the recipient of several prestigious awards including Johnson and Johnson Corporate 2011 Philip B. Hofmann Research Scientist Award in recognition of “Outstanding Achievement in the Field of Research and Development”. Dr. Dai’s research and innovation is focused on the development of biological molecular drugs through formulation and process development, drug delivery technologies/devices, scale-up, and tech transfer/manufacturing. Dr. Dai’s technology innovations have directly led to the launch of commercial drug products, and established development projects. In addition to his industrial contribution, Dr. Dai’s work has resulted in over 50 peer-reviewed journal research articles. Dr. Dai has been a very passionate volunteer in building a strong and collaborative pharmaceutical community. He served as President of SAPA-GP (2014-2015).
maintained dialogues for years with senior executives of renowned domestic and foreign enterprises. Well understanding the strategic planning of customers’ corporate business and human resources, he has conducted interviews with nearly 1,000 middle to high-end management personnel to accumulate in-depth knowledge about talent assessment, career development planning and other aspects. Mr. Eric Duan graduated from Shanghai Medical University with a bachelor degree in clinical medicine.

Dr. Fan was trained at UC, Berkeley in Biostatistics and obtained his doctoral degree from Cornell/Sloan-kettering in structural biology/Immunology. He was further trained by Dr. Gunter Blobel at Rockefeller University. With a dream of using a hybrid approach (by combining computation design and experimental validation) to accelerate drug discovery, and to reform current ‘hit-2-lead’ drug discovery scheme, Dr. Fan founded Accutar biotech with the support of Dr. Gunter Blobel. Dr. Fan also hold a joint appointment at SUNY, Downstate medical school as a research assistant professor.

Mr. Fendrick is President and CEO of Rockland Immunochemicals, Inc. Rockland is a global biotechnology company that is renowned for its development of assays, antibodies and antibody based tools. Rockland conceives and produces monoclonal and polyclonal antibodies against targets involved in cancer and other molecular signaling pathways which are incorporated into immunoassays for detection of biomarkers for various diseases. Partnering with leading government, academic and biopharma institutions and organizations throughout North America, Europe and Asia is a cornerstone of Rockland’s success. For example, in collaboration with the National Cancer Institute’s Center for Cancer Research and the MD Anderson Cancer Center, Rockland recently released a suite of research reagents used to assess patient suitability for certain cancer therapies. Rockland’s proprietary technology and expertise spans a broad spectrum – from Lyme disease assays to VHH single-domain antibody platforms and beyond. Rockland is located in Limerick, Pennsylvania. Jim is a graduate of Gettysburg College.

Dr. Fan is President and CEO of Rockland Immunochemicals, Inc. Rockland is a global biotechnology company that is renowned for its development of assays, antibodies and antibody based tools. Rockland conceives and produces monoclonal and polyclonal antibodies against targets involved in cancer and other molecular signaling pathways which are incorporated into immunoassays for detection of biomarkers for various diseases. Partnering with leading government, academic and biopharma institutions and organizations throughout North America, Europe and Asia is a cornerstone of Rockland’s success. For example, in collaboration with the National Cancer Institute’s Center for Cancer Research and the MD Anderson Cancer Center, Rockland recently released a suite of research reagents used to assess patient suitability for certain cancer therapies. Rockland’s proprietary technology and expertise spans a broad spectrum – from Lyme disease assays to VHH single-domain antibody platforms and beyond. Rockland is located in Limerick, Pennsylvania. Jim is a graduate of Gettysburg College.

Mr. Fendrick is President and CEO of Rockland Immunochemicals, Inc. Rockland is a global biotechnology company that is renowned for its development of assays, antibodies and antibody based tools. Rockland conceives and produces monoclonal and polyclonal antibodies against targets involved in cancer and other molecular signaling pathways which are incorporated into immunoassays for detection of biomarkers for various diseases. Partnering with leading government, academic and biopharma institutions and organizations throughout North America, Europe and Asia is a cornerstone of Rockland’s success. For example, in collaboration with the National Cancer Institute’s Center for Cancer Research and the MD Anderson Cancer Center, Rockland recently released a suite of research reagents used to assess patient suitability for certain cancer therapies. Rockland’s proprietary technology and expertise spans a broad spectrum – from Lyme disease assays to VHH single-domain antibody platforms and beyond. Rockland is located in Limerick, Pennsylvania. Jim is a graduate of Gettysburg College.

Andres Gomez currently heads the Epidemiology, Safety Science and Analytics Team, BMS.

Jie Fan, Ph.D.,
Founder, Accutar Biotech

James Fendrick, BS
President and CEO, Rockland Immunochemicals, Inc.

Dr. Fan was trained at UC, Berkeley in Biostatistics and obtained his doctoral degree from Cornell/Sloan-kettering in structural biology/Immunology. He was further trained by Dr. Gunter Blobel at Rockefeller University. With a dream of using a hybrid approach (by combining computation design and experimental validation) to accelerate drug discovery, and to reform current ‘hit-2-lead’ drug discovery scheme, Dr. Fan founded Accutar biotech with the support of Dr. Gunter Blobel. Dr. Fan also hold a joint appointment at SUNY, Downstate medical school as a research assistant professor.

Mr. Fendrick is President and CEO of Rockland Immunochemicals, Inc. Rockland is a global biotechnology company that is renowned for its development of assays, antibodies and antibody based tools. Rockland conceives and produces monoclonal and polyclonal antibodies against targets involved in cancer and other molecular signaling pathways which are incorporated into immunoassays for detection of biomarkers for various diseases. Partnering with leading government, academic and biopharma institutions and organizations throughout North America, Europe and Asia is a cornerstone of Rockland’s success. For example, in collaboration with the National Cancer Institute’s Center for Cancer Research and the MD Anderson Cancer Center, Rockland recently released a suite of research reagents used to assess patient suitability for certain cancer therapies. Rockland’s proprietary technology and expertise spans a broad spectrum – from Lyme disease assays to VHH single-domain antibody platforms and beyond. Rockland is located in Limerick, Pennsylvania. Jim is a graduate of Gettysburg College.

Dennis M. Gross, Ph.D., is the CEO, Treasurer and Professor of Pharmacology for the Pennsylvania Drug Discovery Institute and Professor of Experimental Therapeutics and Medicinal Chemistry at the Baruch S. Blumberg Institute of the Hepatitis B Foundation. He is also Faculty in the Jefferson College of Biomedical Sciences and the Sidney Kimmel Medical College of Thomas Jefferson University (TIU). He recently retired from full-time status at TIU where he was the Associate Dean for Program Development and Assessment and Director for the Professional Science Masters Programs. He was also Associate Professor of Pharmacology & Experimental Therapeutics in the Jefferson Medical College. Prior to this, he was at the Merck Research Labs for 29 years retiring in 2006 as Senior Director and Head of West Point Business Operations with overall responsibilities for capital planning and facilities in Pennsylvania, California and Massachusetts. He was also responsible for capital lab projects and operations oversight at Merck lab sites in Canada, Japan, Italy and the UK. In his career at Merck & Co. he held a number of positions ranging from bench scientist to head of computer resources, divisional data security administrator, manager of international strategic planning, M&A activities and liaison for basic research and clinical drug development in Japan. During his tenure at Merck, he also served as Adjunct Professor of Global Logistics in the School of Business and Industry of Florida A&M University. He has worked with the Center for Strategic & International Studies in Washington, DC on policy issues relating to biological weapons of mass destruction. He received his BA (1969) and MS (1970) from California State University Northridge and his PhD (1974) from UCLA pursuing a postdoctoral fellowship at Tulane University School of Medicine. He has also participated in executive education programs at Wharton, MIT and the Tufts School of Law and received FEMA NIMS and ICS certification. He is a member of the American Association for Pharmaceutical Scientists, American Chemical Society, American Heart Association, Global STEM Alliance, History of Science Society, International Society for Pharmaceutical Engineering, and Sigma Xi.

Dennis M. Gross, Ph.D.
CEO & Treasurer of Pennsylvania, Drug Discovery Institute

Andres Gomez currently heads the Epidemiology, Safety Science and Analytics Team, BMS.

Dahai Guo, M.S., M.B.A.
Founder & CEO of Humanwell PuraCap Pharmaceutical (Wuhan) Ltd.

Dahai Guo has managed six affiliate companies in US & China. Under Mr. Guo’s leadership, PuraCap Pharmaceutical & its affiliated companies are one of the leaders in specialty pharma & healthcare industry, who is developing, manufacturing and marketing broad range of Branded Rx, Generic Rx and OTC pharmaceutical products in US & the global markets. Currently, PuraCap & affiliates have over 80 different drugs and over 400 products selling in US, China, Canada and other countries. It has four US FDA inspected manufacturing and packaging facilities in US & China. Through his professional career, Mr. Guo has held senior positions in several multi-billion dollar global companies and also start-up companies in biotech, pharmaceutical and healthcare product industry. He had senior management position in global based public companies like Inverness Medical LLC., (now Alere), Ansell Healthcare LLC, Roche
Dr. Sean Hu is currently CEO of Avotres Inc., a clinical stage biotech company with a disruptive platform to develop novel MoA immunotherapies aiming to cure most auto-immune diseases and tackle cancers. Dr. Hu brings more than two decades of broad experience in life science industries and academia. Prior to Avotres, Dr. Hu was Senior Vice President and Head of Consulting for pharmaceutical and diagnostics industries at GlobalData PLC, a public company listed on the London Stock Exchange. Even earlier, aside from founding BioStrat Advisory LLC, for years he was a Managing Partner and Head of Biostat USA, both boutique life science strategy consultancies. His earlier career included IMS Consulting, SDG Life Sciences, AT Kearney, and hands-on industry experience at BMS, Illumina and CuraGen. His broad consulting expertise spans across investment/licensing evaluation, product commercialization, and, strategies for building and growing companies. Dr. Hu is a world class expert in strategic decision-making, as well as a recognized thought leader in the field of personalized medicine strategy. He currently serves on the Editorial Board of the peer-reviewed journal Personalized Medicine. As part of his extracurricular activities, Dr. Hu is a founding Board Member of BioKatalyst, a non-profit US organization whose invited-only members are the top management elites of Chinese Americans crossing healthcare industry.

Zak Huang received medical training from the Nanjing Medical University, and practice medicine in Nanjing, China before moving to the US. There he designed and conducted clinical programs at the University of Minnesota, as well as Boston Scientific and Eli Lilly, until transitioning to regulatory strategy in 2002. After his 11-year tenure at the US Merck (MSD) as Global Regulatory Lead, in 2015, he joined CSL Behring, a global leader of plasma, recombinant protein and vaccine products, and played a significant leadership role. As the Head, Global Product Strategy, he built a strong global regulatory organization to successfully provide science-based, solution-oriented and globally aligned regulatory strategy for all CSL Behring new products. Recently, he assumed the role of Head, China R&D.

Feng Li, Ph.D. is president and one of the founders of Alliance Pharma. He obtained his Ph.D. in Bioanalytical Chemistry jointly from Canadian Doping Control Centre and Concordia University. Subsequently he conducted post-doctoral training in Biomedical Mass Spectrometry Facility at Mayo Clinic. Furthermore, Dr. Li also has a BS in Pharmacy and a MS in Medicinal Chemistry. Professionally, he has held responsible roles in the area of drug discovery metabolism at Phoenix International (now GSK), Pfizer, Eli Lilly and at Johnson and Johnson. Eric has specialized in Neuroscience research, particularly Alzheimer’s disease and other neurodegenerative diseases, for the past 20 years. Eric is a Visiting Professor in the Department for Human Genetics at the Catholic University of Leuven, Belgium and a Visiting Professor in the Department of Molecular Neuroscience at the Institute of Neurology, University College London.

Ning Jia, M.S. is associate principal at KMK Consulting Inc. After graduating from Lehigh University with Master Degrees in both Statistics and Electrical Engineering, Ning has spent last 10 years supporting and leading analytical and operational engagement with various types of clients in health care industry. Her areas of expertise include targeting, call planning, incentive compensation, sales team structure and optimization, marketing science, brand analytics, campaign ROI evaluation and resource allocation. With a comprehensive understanding and hands-on experience of customers’ analytical needs, she leads KMK onshore and offshore analytics group providing managed services in full spectrum of sales force effectiveness, marketing science, advanced brand and commercial analytics and reporting.

Eric H. Karran PhD is a molecular biochemist by training. He is currently at AbbVie where he is Vice President, Distinguished Research Fellow and Site Head of the Foundational Neuroscience Center in Cambridge, Boston. Previously Eric was the Director of Research for Alzheimer’s Research UK. He has held senior positions in a number of companies, including SmithKline Beecham (now GSK), Pfizer, Eli Lilly and at Johnson and Johnson. Eric has specialized in Neuroscience research, particularly Alzheimer’s disease and other neurodegenerative diseases, for the past 20 years. Eric is a Visiting Professor in the Department for Human Genetics at the Catholic University of Leuven, Belgium and a Visiting Professor in the Department of Molecular Neuroscience at the Institute of Neurology, University College London.

Ning is Associate Principal at KMK Consulting Inc. After graduating from Lehigh University with Master Degrees in both Statistics and Electrical Engineering, Ning has spent last 10 years supporting and leading analytical and operational engagement with various types of clients in health care industry. Her areas of expertise include targeting, call planning, incentive compensation, sales team structure and optimization, marketing science, brand analytics, campaign ROI evaluation and resource allocation. With a comprehensive understanding and hands-on experience of customers’ analytical needs, she leads KMK onshore and offshore analytics group providing managed services in full spectrum of sales force effectiveness, marketing science, advanced brand and commercial analytics and reporting.

Eric Karran, Ph.D. is a molecular biochemist by training. He is currently at AbbVie where he is Vice President, Distinguished Research Fellow and Site Head of the Foundational Neuroscience Center in Cambridge, Boston. Previously Eric was the Director of Research for Alzheimer’s Research UK. He has held senior positions in a number of companies, including SmithKline Beecham (now GSK), Pfizer, Eli Lilly and at Johnson and Johnson. Eric has specialized in Neuroscience research, particularly Alzheimer’s disease and other neurodegenerative diseases, for the past 20 years. Eric is a Visiting Professor in the Department for Human Genetics at the Catholic University of Leuven, Belgium and a Visiting Professor in the Department of Molecular Neuroscience at the Institute of Neurology, University College London.

Feng (Frank) Li, Ph.D. is president and one of the founders of Alliance Pharma. He obtained his Ph.D. in Bioanalytical Chemistry jointly from Canadian Doping Control Centre and Concordia University. Subsequently he conducted post-doctoral training in Biomedical Mass Spectrometry Facility at Mayo Clinic. Furthermore, Dr. Li also has a BS in Pharmacy and a MS in Medicinal Chemistry. Professionally, he has held responsible roles in the area of drug discovery metabolism at Phoenix International (a major CRO), in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GSK Pharmaceuticals and in the Drug Metabolism group at Cephalon (Now Teva). Dr. Li has extensive DMPK experience in both the drug discovery and development. He is a recognized expert in the field of bioanalysis and DMPK. He has more than 20 years working experience in CRO, pharmaceutical and biotech industries. Under his team’s leadership, Alliance Pharma was recognized as: 2014 — The Philadelphia 100® Fastest Growing Companies; 2015 — The Philadelphia 100® Fastest Growing Companies; 2016 — SmartCEO’s Future 50 Companies; 2017 — SmartCEO’s Future 50 Companies.
Mr. Ken Li is Managing Partner of Yuanmin Capital, former partner of Mingxin China Growth Fund, and Chairman of BJ Sunforest Capital. Ken’s track record in investment includes CF Pharma, Pharmacodia, Kangdamed, DK Medtech, Sonicmed and Yocally, etc. Before his career as a venture capitalist, Ken worked as GM China for Chiral Quest Inc, a US public company. He completed MBO and raised $18m and 120m Yuan and started up Chiral Quest China, a brand new entity: The company is now at pre-IPO stage. Prior to his managerial track, Ken served as Senior Scientist of Eisai Research Institute and scientist of Wyeth. Ken initiated Tianjin International Joint Academy of Biomedicine (TJAB), he served as Review Panelist of China’s National Thousand Talents Plan Program, Founder of Sino-American Pharmaceutical Association-New England (SAPA-NE) and Member of BayHelix. Ken received his MBA from Babson College, MSc from City College of New York and BS from West China University of Medical Sciences.

Dr. Min Li is Head of Neurosciences R&D at GSK and oversees an R&D organization responsible from target discovery to clinical proof of concept. GSK neuroscience is now based in Upper Providence of R&D hub and focuses on discovering and developing medicines to treat diseases caused by hyper-excitation and neurodegeneration, including Alzheimer’s and Parkinson’s diseases, and pain. Prior to joining GSK in 2014, Min spent nearly 20 years as a faculty member at Johns Hopkins University School of Medicine in Baltimore where he was a tenured Professor of Neuroscience and Physiology. In addition to directing his laboratory independent research programs, he led NIH national programs and university-industry alliances that included long-term partnerships between Johns Hopkins and major fortune 500 companies. Min is an author of more than 100 research papers, patents and books. His research reports have been published in journals including Science, Cell, and Nature. Awards and recognition for his research achievements include the Helen Hay Whitney Fellow, Sloan Neuroscience Fellow, Klingenstein Neuroscience Fellow, the NIH Shannon Investigator Award, Pfizer AHA fellow, and Established Investigator of AHA. He is also a Fellow of the American Association for the Advancement of Science.

Dr. Li has over 20 years of R&D experience obtained in US and China. Dr. Li has worked in US for 15 years in several companies including Eli Lilly, Bayer, Pharmacia, and Roche on a variety of programs. He has led nearly 10 clinical programs and obtained NDA approval from the FDA for one of them. Dr. Li has extensive experience on global drug development, clinical protocol development and trial management, project management, site monitoring and CRO management, regulatory affairs and submission, licensing, interactions with KOLs and VCs, etc. Dr. Li has then worked in Beijing to help Bayer to establish a global development center. He was in charge of clinical development for anti-diabetic and antibiotic drugs in China and AP. He has successfully led the team to obtain CTA approval via Green Channel for an antibiotic drug and conduct a pivotal trial in China/AP for approval of a skin indication. He has also led global teams to develop several life cycle management products for China/AP. Thus, Dr. Li has accumulated rich hands-on experience on clinical research in China and CFDA regulation. Dr. Li has established a clinical research platform in US from scratch. Under his leadership, his team has completed over 10 clinical studies and reached agreement with the FDA on NDA submission via 505 b(2) for 2 projects. He is currently leading a team to prepare a NDA submission and product launch in US. He has interacted with the CFDA to change its regulation by introducing FDA regulation and US practice, and is currently working with EU regulatory agencies. He was also involved in M&A target evaluation and preparation for IPO in HK market.

Song Li, Ph.D., is the founder, President and CEO of Frontage Laboratories, Inc. Dr. Li received his BS degree in Chemistry from Zhengzhou University in 1982 and his Ph.D. in Analytical Chemistry from McGill University in 1992. After two years of post-doctoral research in Pharmacokinetics at the Oncology Department of the Medical School of McGill University, Dr. Li moved to the United States, where he started his career in Pharmaceutical industry and held management positions at Great Valley Pharmaceuticals and Wyeth, and led numerous projects related to the development of pharmaceutical products. Dr. Li has more than 20 years of pharmaceutical industry experience and has written numerous scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Dr. Li has been the recipient of numerous awards, including the ‘Realizing the American Dream’ award from the Pennsylvania Welcoming Society and ‘Outstanding 50 Asian Americans in Business’ award from AABDC, and most recently, the 2018 Healthcare CEO award. In 2001, Dr. Li founded Frontage Laboratories, Inc. to provide integrated services to pharmaceutical companies around the globe. Frontage has grown to a full service CRO with more than 700 employees, assisting biopharmaceutical organizations in their research and product development efforts, including bioanalysis, preclinical and clinical studies, analytical testing, product development support, tox/DMPK and biometrics. Frontage has enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through pre-clinical development to commercial launch in global markets. Frontage has been a winner of the Philadelphia 100, as one of the 100 fastest growing companies in Greater Philadelphia area. Frontage also received the ‘Fast 50’ Award from the USPAAACC and ‘Future 50’
Dr. Bill Liang is the co-founder of CF PharmTech., Inc, a fully integrated speciality pharmaceutical company focused on the development and manufacturing of inhalation products for global market. Dr. Liang has over 20 years' experiences in biomedical research, financing and marketing in both US and Chinese healthcare industries. Prior to founding CF PharmTech, Dr. Bill Liang started and operated two business ventures engaged in consulting and medical product distribution business in both China and the USA since 2002. He has been instrumental in developing successful business partnerships with a dozen of Western clients to promote their business in China. Dr. Bill Liang received his Ph.D. in Molecular and Cellular Biology from the University of Massachusetts at Amherst and a M.B.A. from the University of Southern California, and had his postdoctoral training at the Harvard Medical School. He served his internships in Convergent Venture LLC., a biomedical venture capital firm and Wedbush Morgan Securities, an investment-banking firm in Los Angeles respectively.

Dr. Bo Liang is a serial entrepreneur with over 20 years experience in drug discovery research, chemical and material sciences, biotechnology and materials venture and management. Dr. Liang is Founder and President of IVIEW Therapeutics Inc. focusing on developing ophthalmic and wound care medications. Its lead compound, IVIEW-1201 for ophthalmic indications, is scheduled to start human phase II clinical trials in 2018. He is also co-founder and Chairman of Adesso Advanced Materials, which developed revolutionary re-workable and recyclable epoxy resin systems and were qualified in carbon fiber composites in automotive industry applications, especially for light weight new energy vehicles. He is also Managing Partner of Alpha Bioventure, an Angel Investment Fund dedicating to life sciences innovative projects. In 2006 Dr. Liang co-founded CLS Pharmaceuticals with two ophthalmologists in New York, and advanced an ophthalmic drug project into clinical phase II and successfully licensed it to Foresight Biotherapeutics. Then Dr. Liang served as Executive Vice President of Foresight Biotherapeutics, Inc. (New York) to head the drug program’s further development. The program was acquired by Shire Pharmaceuticals in 2015 for $300 million. He was previously Senior Scientist at Pharmaceopia, Inc. in New Jersey for six years, leading medicinal chemistry development of first-in-class small molecule therapeutics for respiratory and CNS diseases. Dr. Liang holds over 50 issued international patents and patent applications. He was a reviewer for Journal of Bioorganic and Medicinal Chemistry, Dr. Liang is Co-Founder of Sino-American Pharmaceutical Professionals Association-Greater Philadelphia (SAPA-GP) and served as the first President of SAPA-GP from 2002 to 2004. Dr. Liang obtained his PhD in chemistry from the University of Pennsylvania, MBA from the Stern School of Business of NYU, and Bachelor of chemistry from Peking University in China.

Xianchen Liu, Ph.D., M.D.
Senior Medical Director, Pfizer

Dr. Liu is Senior Medical Director at Pfizer and visiting professor of epidemiology, psychiatry, clinical psychology, and health outcomes research at Shandong University, South China Normal University, University of Tennessee Health Science Center and research fellow of the University of Pennsylvania's Center for Public Health Initiatives (CPHI). Dr. Liu obtained his medical degree from Shandong Medical University and PhD in mental health at University of Tokyo. He did postdoctoral research in clinical/environmental epidemiology at National Institutes of Health (NIH). He was assistant professor of psychosocial epidemiology at Arizona State University Prevention Research Center and assistant professor of Psychiatry at University of Pittsburgh before he joined Lilly as senior research scientist in health economics and outcomes research. His research interests and experiences include behavioral and chronic disease epidemiology, sleep, mental health, community-based interventions, health economics and outcomes research, real-world data, and clinical trials. For over 30 years, Dr. Liu has done clinical and epidemiological studies, health outcomes research and real-world studies in China, Japan, and the US. He has published more than 110 SCI papers in JAMA Psychiatry, JAMA Pediatrics, and International Journal of Epidemiology, etc. He has developed 4 measures for medical and psychological research. He has served as associate editor of SLEEP AND BIOLOGICAL RHYTHMS and a reviewer for more than 35 SCI journals.

Brad Loncar, B.A.
CEO, Loncar Investments

Brad Loncar is an independent biotech investor and analyst, and has managed a biotech-focused family office since 2008. Through Loncar Investments LLC, he uses his research of biotech companies and technologies to develop equity indexes that are focused on precise investment opportunities. His first two products are the Loncar Cancer Immunotherapy Sector Index and the Loncar China BioPharma Industry Index. Brad previously worked at Franklin Templeton Investments and served in a Senior Advisor role at the U.S. Department of the Treasury. He is one of the most followed biotech commentators on social media, a regular panelist at biotech conferences, and writes biotech commentary at www.LoncarBlog.com. He holds a BA in Finance from the University of Miami.

Zhiping Liu, J.D.
Partner, Liu, Zheng, Chen & Hoffman LLP

Mr. Zhiping Liu focuses his practice on corporate transactions, concentrating in venture capital funding for start-up companies, mergers and acquisitions and general corporate governance matters. Mr. Liu has experience assisting clients in structuring and consummating over 100 corporate transactions totaling over $7 billion in value, including mergers, acquisitions, financings, restructurings and corporate reorganizations. Mr. Liu received his JD from NYU Law School and practiced for about 7 years with major Wall Street and Silicon Valley law firms before founding Liu, Zheng, Chen & Hoffman LLP, a boutique corporate and intellectual property law firm.
Andrea McIntire, M.S.
Human Resources Manager and Professional Coach, GSK

Andrea McIntire, MS, SPHR, CPC, is an accomplished Human Resources Professional and Professional Coach. Andrea leverages her over 20 years of business experience in fortune 500s and non-profit organizations, including GlaxoSmithKline (GSK), Lockheed Martin, The Wistar Institute, various healthcare organizations, and the IQ Group, an IT consulting firm. As an HR practitioner at GSK, Andrea consults, advises and engages with leadership to facilitate effective HR initiatives including organizational design, transformational change, and employee engagement strategies. Andrea realized her deep interest and ability to connect with people through coaching. As a result, she completed formal training to become a Certified Professional Coach (CPC) from the Institute for Professional Excellence in Coaching (iPEC). Through coaching, Andrea works with deep scientific experts and other STEM professionals to grow technical specialists into strong, and confident leaders. Andrea also works with professionals new to the US, to help clients excel in the US work environment. Andrea's expertise in emotional intelligence and well-being initiatives allows clients to evaluate their current situations and take positive steps to achieve goals. Andrea holds a BA in Psychology from West Chester University and an MS in Human Resources Development from Villanova University. Andrea also holds a Senior Professional in HR (SPHR) certification from the Society for Human Resources Management.

Christopher P. Molineaux, B.A.
President & CEO, Life Sciences Pennsylvania

As president & CEO of Life Sciences Pennsylvania, Christopher Molineaux serves as the chief advocate and spokesman for the life sciences industry that calls Pennsylvania home. Molineaux oversees the strategic direction for the association, assuring Life Sciences Pennsylvania continues to be the catalyst that makes Pennsylvania the top location for life sciences companies. Molineaux brings to Life Sciences Pennsylvania more than 25 years of experience in the bio-pharmaceutical and health care industries, with front-line experience in developing and executing strategies to navigate a shifting economic and political environment.

Prior to joining Life Sciences Pennsylvania in September 2009, Molineaux served as worldwide vice president of pharmaceutical communications and public affairs for Johnson & Johnson. He began his Johnson & Johnson career as vice president of corporate communications at Centocor in Malvern, PA, and was later promoted to vice president for communications of Johnson & Johnson’s global Biotechnology, Immunology & Oncology (B.I.O.) business unit. Molineaux previously served as vice president of public affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA).

Prior to his role at PhRMA, he was vice president, communications and marketing at the Blue Cross and Blue Shield Association, developing public awareness and education strategies related to commercial and government payer systems. Molineaux also worked as a public affairs executive for the federal Departments of Health and Human Services (HHS) and Agriculture, and as a press officer on the White House staff of President George H. W. Bush.

In addition to leading Life Sciences Pennsylvania, Chris Molineaux serves as a non-executive Director of Aclaris Therapeutics, the Chester County Economic Development Council, and the Valley Forge Tourism & Convention Board. He also serves on the Advisory Boards of BioAgility of Durham, NC and St. John Vianney Church of Gladwyne, PA.

Peter (Peizhi) Luo, Ph.D.
Founder and Chief Executive Officer, Adagene

Dr. Peter (Peizhi) Luo, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. He utilizes a multi-disciplinary approach to his work, combining methods from experimental and computational biology, chemistry, and physics. Prior to this, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologies Technology at Merck & Co., Inc. Before the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. During Dr. Luo’s time at Merck, he designed and built the antibody libraries and engineering platforms that propelled the discovery of Merck’s novel biologics. He received two Merck Special Achievement Awards for his leadership and scientific contribution. Before his work at Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Through his work at Stanford, Dr. Luo discovered the fundamental mechanisms of protein folding and stability concerning the solvation of peptide backbone by cosolvents and amino acid side-chains. Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago. M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

Ian J. Reynolds, Ph.D.
VP of Discovery Research, Teva Pharmaceuticals

Born in London, Ian earned a B.Sc. in Pharmacology from Leeds University. Ian received his Ph.D. from Johns Hopkins University School of Medicine, and then completed a post-doctoral fellowship at the University of Chicago. He joined the Department of Pharmacology at the University of Pittsburgh in 1988. There, Ian’s research focused on cellular mechanisms of neurodegeneration and glutamate receptor pharmacology. Additionally, his laboratory studied mitochondrial function and trafficking in neurons. Ian moved to Merck Research Laboratories in 2005, where he led drug discovery groups focused on ophthalmology, stroke and Parkinson’s disease. Ian joined Knopp Biosciences in 2012 as the head of Biology Research. In 2013 Ian moved to Teva Pharmaceuticals to establish the CNS Discovery group based in West Chester. He currently heads Small Molecule Discovery at Teva, and is focused on drug discovery and development in neurodegeneration, migraine and pain.
Alfred Saah, M.D.
Executive Director in the Global Center for Scientific Affairs, Merck&Co.

Alfred Saah is Executive Director in the Global Center for Scientific Affairs at Merck Research Laboratories near Philadelphia, Pennsylvania. He attended the University of Maryland, School of Medicine and the Johns Hopkins University School of Public Health. He subsequently trained and worked at the National Institute of Allergy and Infectious Diseases for 7 years and the Johns Hopkins School of Public Health and School of Medicine, where he was on faculty for 10 years. He is board certified in internal medicine, infectious diseases and in preventive medicine (epidemiology). While at the NIH, he co-founded the Multi-center AIDS Cohort Study and was its Principal Investigator at Hopkins until moving to the Merck Research Laboratories in 1997. His research and clinical activities throughout his career at NIH, Hopkins and at Merck Research Laboratories include HIV-related therapies and vaccine research, most notably clinical co-development of the 4-valent and 9-valent HPV vaccines. He currently is Global Director for Scientific Affairs for Vaccines and heads the Vaccines Merck Investigator-initiated Studies Program.

Fang Shen, Ph.D.
Principal Scientist, Janssen R&D

Dr. Fang Shen is a Principal Scientist and project lead for multiple early drug discovery programs in Janssen R&D, pharmaceutical company of Johnson & Johnson. Fang and his team are responsible for identification & validation of novel drug targets; understanding molecular mechanism of drug action; and progressing pre-portfolio projects into early development. Prior to that, Fang worked at Genentech for over two years as a key member of early drug discovery team. Dr. Shen got his postdoctoral training in Dr. Sarah Gaffen’s lab at SUNY Buffalo, one of the leading groups on IL-17 receptor biology. He published multiple papers on IL-17 receptor configuration, signal transduction, and role of IL-17 in host defense. Dr. Shen got his Ph.D in Institute of Materia Medica, CAMS & PUMC (中国医学科学院中国协和医科大学药物研究所), where he is one of the major contributors of early stage research of Imrecoxib, a novel cyclooxygenase-2 selective inhibitor to treat arthritis pain marketed in China in 2011.

Jae Sly, Ph.D., M.B.A.
VP, Corporate Development and Innovation Lab Operations, ACROBiosystems

Jae Sly is the VP, Corporate Development and Innovation Lab Operations for ACROBiosystems. Jae has over 20 years in the Biopharmaceutical Industry, from R&D to Clinic. Jae is an Industry Leader providing strategic partnering of Biopharma technologies and services. One such technology, implemented innovation that launched single-use manufacturing. Jae has initiated cross border partnering platforms, investment forums and is a corporate mentor in the Delaware and Maryland Incubator Startup Programs for Entrepreneur Professional Series. Collaborations, Contract negotiations and technology evaluations for Investment Opportunities, has been primary expansion within Jae’s portfolio of services in last several years. Jae maintains a strong Industry presence by presenting and attending at major conferences. Jae received her Ph.D. in Immunology from University of Washington and MBA from San Diego State University. Jae is a member of LES, ICOY, ESACT and BFO.

Lauren Schwartz, B.A.
Senior Director, International Business, Department of Commerce, City of Philadelphia

In her role as Senior Director of International Business for the City of Philadelphia at the Department of Commerce, Lauren Schwartz leads initiatives to grow Philadelphia’s international business and relationships. With a focus on global business attraction, foreign direct investment, and promoting exports, her work creates jobs and strengthens the local economy. She plays a leading role in crafting the global strategy for Philadelphia and hosts delegations, diplomats, business and investors from abroad, and representing the City of Philadelphia worldwide. Previously Lauren served as the Deputy Director at the non-profit trade association, Food Export USA – Northeast, working with promote U.S. exports in over 40 countries around the world. Funded by USDA, this public-private partnership produced over $500 million in export sales annually. Lauren also has experience running her own consulting firm specializing in international project management and food marketing. She has worked in Copenhagen, Denmark at an international university where she facilitated programs for students of European politics, business and economics. Lauren is a Fellow of the Leadership Philadelphia Core Class of 2016. She is on Board of Directors for the non-profit Women Against Abuse in Philadelphia. She earned a B.A. in Communications at Randolph-Macon Woman’s College with minors in Business Economics, Spanish and Philosophy. She speaks some Danish and Spanish and has traveled for work and pleasure to over 25 countries.

Le Sun, Ph.D.
President and CEO, AbMax Biotechnology Co., Ltd.

Dr. Sun, CEO & President of AbMAX Biotechnology, Inc., Adjunct Prof. of Beijing Normal University, Beijing’s Thousand Talent, Executive member of ABO. Dr. Sun has more than 30 yrs experience in antibody-based cell signaling research and drug development. Dr. Sun received his PhD in biochemistry/cell biology from Tsinghua University (Beijing) in 1989, working on EGF cell signaling. Dr. Sun was a postdoctoral fellow in Dr. David Barnes’s lab at Oregon State University, working on embryonic stem cells. Dr. Sun was Director of R&D at Upstate Biotechnology Inc., a market leader in the biotechnology research reagent sector for cancer biology. His team introduced 200+ new antibodies and enzymes every year. In 2000, as a co-founder and the President, Dr. Sun started A&G Pharmaceutical in Baltimore with $250K seed fund, created the record of “Generation of mAb in 28 days” for MedImmune and received $2.5 M investment from MedImmune in 2001. In 2004, Dr. Sun returned to Beijing, China, and started Welson Pharmaceuticals working on antibody drug conjugate (ADC), now has one leading candidate in co-development with a Chinese Pharma. In 2006, Dr. Sun started AbMAX as a Biotech CRO. Using AbEpiMax, the ONLY B cell-epitope identification program, his team has generated >10,000 antibodies against over 5000 different targets, many of which have been published in well-known journals such as Nature Medicine. His team has been recognized by its clients as the one of the best monoclonal antibody development companies. His team also has extensive experiences in establishments of assays for immunogenicity and PK study of antibody drugs and other biologicals.Currently he is leading a team in “AI-powered Antibody Drug Development”. Dr. Sun has published 40+ papers on journals such as Nature Med., Nature Genetics, Immunity, Development Cell, etc. He holds 8 issued patents and filed many.
Mr. Taylor is the Life Sciences Team Niche founder, Lead broker and consultant to complex Life Sciences (LS) accounts, executive relationships, program design, risk advisory, service oversight. He was the managing director of Life Science Practice, Area President, Wilmington, NC; Partner, President, Walker Taylor Agency, Wilmington, NC- founded 1866; Director of SE Cell Captive Mountain View Indemnity; Casualty Underwriter for Hartford Insurance Group. He is licensed in all 50 states and has transacted business in over 50 countries. He got his bachelor from Clemson University, B.S. major in administrative management. Also, he is Chartered Property and Casualty Underwriter (CPCU) and associate in Risk Management (ARM).

As Vice President of Pharmaceutical Sciences, Allen is responsible for leading drug product formulation development (oral, sterile, biologics, specialty drug delivery routes of administration), analytical testing, device development, and clinical supply manufacture at Merck. Before assuming his current position, Dr. Templeton held positions of increasing responsibility within Pharmaceutical Sciences. Dr. Templeton earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill. He has published over 50 articles, served as co-inventor on 11 patents and authored over 120 presentations in the area of pharmaceutical product research. He has organized a number of symposia and training courses on diverse topics within the field of pharmaceutical research, most notably around his interest in drug product stability. Dr. Templeton is an active member in a number of professional organizations, including the American Association of Pharmaceutical Scientists (AAPS), International Pharmaceutical Federation (FIP) and the American Chemical Society (ACS). He is currently on the board of directors for AAPS and was named as a Fellow of the Association in 2015 for his scientific achievements. He was elected to both the 2010-2015 and 2015-2020 terms of the United States Pharmacopeia (USP) expert committee on physical analysis. He participates on an advisory board and has taught courses in an adjunct role with Purdue University. He also currently serves on editorial advisory boards for the Journal of Pharmaceutical Sciences and American Pharmaceutical Review.

Dr. Jason Uslaner leads the Merck Neuroscience group at West Point focused on discovering novel symptomatic agents to treat pain, neurological, and psychiatric disorders. He also has responsibility for clinical development, co-chairing multiple clinical programs focused on treatments for CNS disorders, while his group provides scientific support for Merck’s Neuroscience marketed products such as Belsomra. Prior to joining the Neuroscience group, Jason was in charge of setting up Merck’s world-class non-human primate lab supporting various Neuroscience projects. He has published over 60 manuscripts in peer-reviewed journals and book chapters and in his 12 years at Merck has been impactful in the advancement of multiple different mechanisms from discovery to the clinic. Prior to joining Merck, Jason received a B.A. from University of California Berkeley, and completed his Ph.D. and postdoctoral studies at The University of Michigan.

Dr. Jim Wang is the Head of Regulatory Affairs Strategy at Spark Therapeutics. He has more than 14 years of global regulatory experience managing full-spectrum global drug development, marketing applications, and regulatory approvals for biologics, gene therapy, small molecules, and device drug combination products. Recently, he led the regulatory submission and approval for Luxturna, the first gene therapy treating a genetic disease in the US. He led pre-submission meetings with FDA and EMA, development of product labeling, risk management plans, and submission documents. He managed agency interactions during product review, FDA advisory committee meeting, and labeling negotiations leading to the approval in US. Previously, he was an executive director at Shire pharmaceuticals responsible for implementing a consolidated global regulatory strategy to secure approval and market access for rare disease biological products through all development phases and life-cycle management. Prior to Shire, Jim was a senior director at Novo Nordisk responsible for global health authority interactions (e.g. FDA, EMA, PMDA, COFEPRIS, Health Canada, and China’s FDA), marketing applications (e.g. NDA, MAA, NDS, etc.), and approvals for Saxenda®, a weight management product. He also held senior positions in BMS, Sanofi, and Wyeth. Jim received his Ph.D. from the University of Illinois at Champaign-Urbana, MBA from Pennsylvania State University, and a B.S. from Jilin University in China.

Simoon Record is the largest and most experienced CRO company in the field of vaccine clinical trials in China. Since established in 2008, hundreds of vaccine clinical trials have been conducted. It helped dozens of vaccines to be successfully approved to the market, including several new drugs. China has a vast territory, a large population and a complex epidemic. Researcher Wei Pengchong has led his team to carry out clinical trials for a long time. By designing large epidemiological surveys and long-term tracking of the epidemic trend of Chinese diseases, A new model based on the basis of epidemiology and drug characteristics to select appropriate investigational sites and down to detail scientifically design the protocol. It helps the sponsor to find the most appropriate time and investigational institutions for clinical trials. Simoon Record constantly develop and prompt institutions to execute high quality vaccine clinical trial. The vaccine products of the sponsor can be evaluated more objectively and effectively, avoiding the interference of all kinds of confounding factors to the clinical study results. Annual endemic epidemic trend is introduced into multicenter clinical study in this new model, which can guarantee certain target cases be obtained in the efficacy trials. In recent years, Researcher Wei Pengchong, led his team to organize EV71, HPV, ROTA, nasal spray flu, PCV, and tetravalent influenza vaccine, all of which are the beneficiaries of this innovation model. Appropriate timing and high proportion of target subjects under the same sample size, tremendously saved sponsors’ time and economic cost.
Danyi Wen, M.D., M.B.A.
President & CEO, Shanghai LIDE Biotech Co., Ltd

Dr. Danyi Wen is President & CEO of Shanghai LIDE Biotech Co. Ltd, a company focusing on translational medicine services at both pre-clinical and clinic setting. Shanghai LIDE has two subsidiary companies: Xian LIDE and Shanghai LIWEN. LIDE is pre-clinical CRO, LIWEN is a third party independent clinical testing lab with CAP certification. LIDE was public listed on New Third Board on Aug 2016. Prior to LIDE, she was Vice President of Biology at Shanghai ChemPartner. She worked with her colleague established ChemPartner biology department from scratch. Prior to ChemPartner, Danyi Wen is a group leader at Preclinical and Clinical Development Science Dept (PCDS) of Biogen-Idec, focused on large molecule immunogenicity assay development, biomarker identification and GLP operation. Prior to Biogen, Danyi worked at Inflammation Department of Millennium Pharmaceuticals, Inc. for 10 years. Prior to Millennium, Danyi Wen hold two years faculty position (Instructor of Medicine) at Dept of Hematology/Oncology at Harvard Medical School /Brigham&Women’s Hospital after 3 years postdoctoral training with Dr. Franklin Bunn. She got her M.D from the Fourth Military Medical College, MS of Biochemistry & Pathology from Chinese Academy of Medical Sciences / Peking Union Medical College and MBA from Suffolk University. She is an adjunct Professor of Pudan University, School of Pharmacy. She is also invited as a Visiting Professor at Translational Medicine Center at Peking Union Medical University (PUMC). 2013, Danyi was selected as “Thousand Talent” at shangh. Dr. Wen has previously worked as a formulation scientist in the Product Line Extension division at GSK and in the R&D headquarter for Consumer Health Care Division at Pfizer (Wyeth). After returning to China, he became the head of the State Key Laboratory of Ministry of Science and Technology for Advanced and Novel Controlled Release Technologies and also served as an executive director at Wuxi Apptech.

Gilbert Wen, Ph.D.
Founder, Overseas Pharmaceuticals Ltd.

Dr. Gilbert Wen is the founder of Overseas Pharmaceuticals Ltd, a specialty pharmaceutical company focusing on developing modified release platform technologies and applying these proprietary technologies to develop NDA products in collaboration with transnational pharmaceutical companies. Among many honors and recognitions, Dr. Wen is a distinguished expert of the Thousand Talent Program (entrepreneurial category) in China and a committee member of Pharmaceutics in Chinese Pharmaceutical Association. In addition, Dr. Wen is a recipient of Distinguished Alumni of Medical School of Beijing University. He holds 8 granted patents and authored a chapter in the book “Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice.”

Zhenhua Wu, Ph.D.
President, SAPA-GP, VP, Head of Preclinical Development at United Neuroscience

Dr. Zhenhua Wu is a senior discovery and development leader with more than 20 years’ experience and a deep understanding of the R&D value chain. He is currently Vice President, Head of Preclinical Development of United Neuroscience, overseeing strategy and execution of preclinical research and development. Prior to UNS, he was Director of Neuroscience Therapeutic Area at GlaxoSmithKline, where he served as a global project lead focusing on therapies for neurodegenerative and neuroinflammatory diseases. He was responsible for directing virtual drug discovery pipeline through partnering with external groups, such as biotech, academic groups and CROs, toward to proof-of-concept studies. Zhenhua had worked in various functional areas in Merck & Co. for ten years where he led various neuroscience projects and delivered several preclinical candidates and served as a global externalization lead. Zhenhua received his Ph.D. degree in neuroscience from University of Rochester and M.S. degree in cell biology from Shanghai Institute of Cell Biology, Chinese Academy of Sciences. Zhenhua holds a certificate in Regulatory Affairs. He has published extensively in the field of neuroscience including publications in prestigious journals such as Nature, Nature Medicine, Neuron and Stroke. He is also a recipient of Hugh Davson Distinguished Award in Neurovascular Biology. Zhenhua serves as the President (2017-2018) of Sino-American Pharmaceutical Professional Association – Great Philadelphia (SAPA-GP).

Tracy Xu, M.B.A.
Area Vice President, Arthur J. Gallagher Inc.

At Arthur J. Gallagher, Tracy advises domestic and multinational corporations on commercial insurance and risk management. As a member of the firm’s Asia Pacific Practice Group, she advises Chinese and Asia Pacific clients for their operations in the U.S.. Prior to joining A.J. Gallagher, Tracy held various management positions for AIG in Chicago, New York and Hong Kong for 10 years, overseeing growth and profitability of various insurance lines of business in the U.S. and across Asia. Tracy’s experience in China ranged from establishing the China office for A.O. Smith in Beijing and handling mergers and acquisitions, to gaining valuable insights working with the China Classification Society and the US Embassy’s Foreign Commercial Service in Beijing. Tracy is also a business consultant and cross cultural expert. She has trained and coached individuals, business executives and teams from small to large corporations on issues related to cross cultural communication, cross border management, team building and personal integration and growth. She received coaching training from Vistage, the largest CEO organization for peer advisory groups and one-on-one executive coaching. She also attended Wright Institute for social and emotional intelligence studies. She is the founding Board Member and President for the non-for-profit organization “China Executive Club”, where she leads Chinese Executives’ peer advisory groups. Tracy is an active public speaker. She has been interviewed by various media such as the Chicago Tribune, the South China Morning Post, and National Public Radio. She speaks frequently in conferences on China-US business, risk management, cross cultural management and leadership, social and emotional intelligence related topics. Tracy has received an MBA from University of Wisconsin-Madison.

Steve Q. Yang, Ph.D.
EVP, CBO & CSO, WuXi AppTec

Dr. Steve Yang is Executive Vice President and Chief Business Officer and Chief Strategy Officer of WuXi AppTec. He is also WuXi’s Head of Research Service Division. His responsibilities include management of multiple business units and corporate strategic planning and commercial operation. WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical
device R&D capability and technology open access platform company with operations in China, US, and Europe. Dr. Yang is a pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed AstraZeneca, based in Shanghai. Previously, Dr. Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer’s global R&D strategic management group based in the United States. Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude from Michigan Technological University. He co-founded the BayHelix Group, a non-profit global professional organization of Chinese life science business leaders, and served as the chairman of the board for two terms.

Dajun Yang, Ph.D., M.D.
Chairman & CEO, Ascentage Pharma Group Corporation, Ltd.

Dr. Dajun Yang, M.D., Ph.D., co-founded Ascentage Pharma Group Corporation, Ltd. in 2009 and serves as its Chairman and Chief Executive Officer. Dr. Yang serves as its Senior Vice President of Research at Ascenta Therapeutics Inc. and General Manager of Ascenta Shanghai R & D Center, a subsidiary of Ascenta Therapeutics Inc. He is a Consultant at Efung Capital. Dr. Yang co-founded Ascenta Therapeutics Inc. in 2003 and served as its Research & Preclinical Development Advisor. Previously, he served as an Associate Professor of Internal Medicine in the Comprehensive Cancer Center at the University of Michigan. Dr. Yang served as a Doctoral Tutor at Sun Yat-Sen University Cancer Center. He was one of the founders of Yasheng Biopharmaceuticals Co., Ltd. In 1995, Dr. Yang joined the Georgetown University Medical Center (GUMC) as an Assistant Professor in the Department of Biochemistry and Molecular Biology and a Senior Investigator in the Lombardi Cancer Center, a position he assumed in 1999. In 2001, he was promoted to Associate Professor. Dr. Yang is one of China’s experts for the “1000 Plan." He completed his Postdoctoral training in the Carcinogenesis Laboratory at Michigan State University in 1993 and at the Lombardi Cancer Center as a SPORC (Specialized Program of Research Excellence) Postdoctoral Fellow in Breast Cancer in 1995. In 1992, Dr. Yang received his PhD. in Genetics from Michigan State University. He obtained his Master of Medicine in Oncology in 1986 from Cancer Center, SUMS, China. Dr. Yang obtained his Medical Degree in 1983 from Sun Yat-sen University of Medical Sciences (SUMS).

Sean Zhang, M.D.
Chief Executive Officer, Hengrui Therapeutics, Inc.

Sean Zhang, MD, FCP is the Chief Executive Officer of Hengrui Therapeutics, Inc. (HTI) located in Princeton, NJ. Prior to HTI, Dr. Zhang worked as Senior Medical Director of Translational Medicine/Early Drug Development at GlaxoSmithKline (GSK), Medical Director and Liaison to China R&D at Bristol-Myers Squibb (BMS). Prior to BMS, He was a Clinical leader in the Department of Translational Medicine/Early Development at Johnson and Johnson. Dr. Zhang also devoted several years of his early career to drug R&D at Merck/Schering-Plough Research Institute. Trained as a Gastroenterologist, Dr. Zhang also obtained his clinical fellowship training in Clinical Pharmacology at the National Institute of Health (NIH) Clinical Center, focusing on clinical pharmacology and early drug development. Dr. Zhang has organized/co-organized several international conferences and was a keynote speaker for many international conferences. He has published more than 30 peer-reviewed papers and received numerous awards.

Alex Zhavoronkov, Ph.D.
CEO, Insilico Medicine, Inc., CSO, the Biogerontology Research Foundation

Dr. Zhavoronkov specializes in the development of the next-generation artificial intelligence and Blockchain technologies for drug discovery, biomarker development and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties and launched multiple research and consumer oriented biomarker systems including the popular iPANDA system and Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and diversity.AI initiative. Since 2012 he published over 80 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy”. He is also the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a Master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is also an adjunct professor in artificial intelligence at the Buck Institute for Research on Aging.

Biao Zheng, M.D., Ph.D
CSO, GenFleet Therapeutics

Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his MS and PhD in Immunology from Fudan University School of Medicine and King’s College, University of London, respectively. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center 1996-1999. He has been a professor in the Department of Pathology and Immunology, Baylor College of Medicine since 1999. Dr. Zheng joined GlaxoSmithKline R&D Center in 2010 as the head of Immunological Discovery Sciences. In 2015, he joined Johnson & Johnson as vice president in Global Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific. He recently joined GenFleet Therapeutics as the Chief Scientific Officer. Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.
Huanxue Zhou, M.S.
Director of Health Economics & Outcomes Research, KMK Consulting, Inc.

Huanxue Zhou is Director of Health Economics & Outcomes Research at KMK Consulting, Inc. She obtained her Master Degree in Statistics from Lehigh University. In her current role, she trains and leads HEOR analysts to execute HEOR studies to support clients. She is responsible for understanding clients' need and ensuring the successful implementation of assigned projects. She provides consultation on appropriate research design, statistical analysis and interpretation of results. In the past seven years, she had many conference posters and peer-reviewed publications with clients resulting from executing high-quality real-world data analyses in various therapeutic areas using a variety of observational databases.

De-Min Zhu, Ph.D.
President and CEO, Curelong Group

De-Min obtained his Ph.D. degree in Physical Chemistry at Peking University, China. After 6 years of cross disciplinary scholar research at NIH and Harvard Medical School in biochemistry, biophysics, immunology, and cancer research, De-Min joined Merck and then Pfizer where he developed his career and leadership in biopharmaceutical formulation/process for vaccines, biologics, and drug delivery. With a VC investment, De-Min founded Cureport, Inc. in 2012 at Boston, MA. At Cureport De-Min invented and patented nPort™ nanotechnology that brought pharmaceutical a revolutionarily platform for liposome manufacturing from milligram to kilogram scales with adjustable particle size and robust reproducibility. In 2016, De-Min and his investors established Curelong (开瑞龙) Pharmaceutical Co. Ltd. at Beijing, China and exclusively licensed Lymphcelle™ nanotechnology from Chinese Academy of Sciences with a 110 million RMB agreement. The two parties also collaboratively launched a Nanomedicine Research Center. Curelong recently signed several essential agreements with Beijing Daxing District to establish the first International Nanomedicine Base in the world. Daxing has provided Curelong with a new 9,000 m² building at its Bio-Pharmaceutical Industry Base to build up Curelong’s nanomedicine pilot plant. De-Min serves as CEO for both Cureport and Curelong.

De-Min published more than 30 peer-reviewed research articles. The equation he derived at Harvard Medical School for the determination of the two-dimensional binding constant (2D Kd) of laterally mobile cell surface proteins was widely cited in the literature as Zhu-Golan Equation in honoring De-Min’s essential contribution to the study of the 2D binding of proteins.
ACROBiosystems is a leading manufacturer of recombinant protein. We provide high quality protein reagents to the pharmaceutical research community. The company employs an application-oriented product development strategy, with a particular focus on protein labeling technology. Our flagship MABSOL® Biotinylated protein collection offers a new set of solution to assay development. These pre-labeled products have been successfully adapted to Biacore, Alphalisa, MSD, among other established platforms.

ACROBiosystems’ catalog includes a comprehensive list of disease associated biomarkers and drug targets from human and other commonly used experimental species. All products are built with high quality with minimal batch variations to satisfy the rigorous standard of pharmaceutical research.

ACROBiosystems keeps growing and adapting by bringing more value to our clients. The addition of the Innovation Lab in Wilmington, Delaware, where ACROBiosystems provides the right blend of innovation and technology. Our scientists have implemented and mastered numerous assay platforms over the years. Our recent introduction of the Innovation Lab offers TCR and BCR NGS Technology and the MSD SQ120 multiplex into our assay development portfolio.
Your Trusted Partner in Pharmaceutical Discovery and Development

CORE CAPABILITIES
Alliance Pharma is a Contract Research Organization (CRO) specializing in bioanalytical services for drug discovery and development of both small and large molecules.

Our Extensive and Diverse Industry Experience Includes:

- Immunoassay-based bioanalysis for large molecule PK/TK, immunogenicity, and biomarkers
- Cell-based assays to monitor biomarkers and cell proliferation
- LC-MS/MS based bioanalysis of drugs and drug-related metabolites and biomarkers
- LC-MS/MS based protein characterization and quantitation
- In vitro drug metabolism (metabolic stability, enzyme inhibition and phenotyping, CYP induction), tissue and protein binding, blood/plasma partitioning, drug transport/permeation
- In vivo rodent PK/TK (AAALAC-accredited Vivarium)
- Drug testing and clinical biomarker assay (CLIA-licensed lab)
- LC-MS/MS based agrochemical and food ingredient analyses
- Biorepository services for short- and long-term storage of a broad selection of sample types and materials

FIND OUT MORE
Please call us at 610-296-3152 or email info@alliancepharmaco.com

www.AlliancePharmaCo.com
Welcome to Xinxiang Pingyuan Demonstration District

Pingyuan Demonstration District of Xinxiang, established in February 2010, has been included in the national key development area of the main function area in Henan and key area of the Zhengzhou–Luoyang–Xinxiang Self-dependent National Innovation Demonstration Area separately in 2014 and 2016. Covering 295 square kilometers, Pingyuan Demonstration District is separated from Zhengzhou by the Yellow River and connected with Zhengzhou by three bridges. It takes only 30 minutes from here to the center of Zhengzhou and Zhengzhou High-speed Railway Station and 40 minutes to Xinxing International Airport, Zhengzhou Airport and Zhengzhou–Europe Freight Station. A convenient transport network is formed by G45 Expressway, Zhengzhou–Jiaozuo–Jincheng Expressway, 107 National Highway, 327 National Highway, Beijing–Guangzhou High-speed Railway, Zhengzhou–Jinan High-speed Railway and the Zhengzhou–Xinxiang Interprovincial Light Railway which is in planning. Pingyuan Demonstration District has set its development goals as participating in the new strategies of China and Henan Province, and being the bridgehead of Zhengzhou–Xinxiang integration, central city of Yellow River economic zone, pioneer of reform and opening-up, growth pole of Xinxiang’s development. Its three main industries which are healthcare industry, electronic information industry and high-end equipment manufacturing industry will be developed energetically.

Central Plains Biomedicine Industrial Park

Following the trend of economic globalization, and industrial gradient transfer law, Pingyuan Demonstration District establishes medical health as the leading industry, and sets up the investment attraction platform Central Plains Biomedicine Industry Park. With a planning area of 2.88 square kilometers, this Park aims to build six functional zones including Biomedicine Core Office Area, Biomedicine R&D Pilot Test Area, Biomedicine Industrialization Agglomeration Area, Biomedicine Outsourcing Area, Biomedicine Logistics Area, and Biomedicine Supporting Service Area. In April 2012, this Park was been listed as Henan-based strategic emerging industrial demonstration area by Henan Provincial Government.

Themed by "biomedicine", and focusing on blood products, vaccine products, biomedicine outsourcing, and biomedicine logistics service, Central Plains Biomedicine Industry Park prioritizes stem cell treatment, biological material, bioengineering agent, biological diagnosis reagent, and emphasizes the new-type therapeutic vaccine and monoclonal antibody drugs with proprietary intellectual property rights and huge market potentials.

Central Plains Biomedicine Industrial Park can provide various biomedicine enterprises with three public service platforms such as pilot test service, incubator service, and accelerator service.
关于我们

奥火（上海）企业管理咨询有限公司(ArcaneFire(Shanghai)RecruitingCo.,Ltd.)，以下简称AF)，是一家服务于医疗大健康行业，提供领先的招聘咨询和人力资源解决方案的服务机构。尤其专注于医疗健康及生命科学产业，建设人才高地，助力企业创新，协助行业发展与腾飞。

AF由一支高素质、精细化、专业化的资深顾问组成，成单数量及质量远高于市场平均水平。其团队顾问曾经为罗氏、诺华、阿斯利康、安进等公司中国新药研发中心的建立提供了巨大的人才招聘支持。

凭借资深的顾问团队优势，AF已经与数家全球顶尖的医药公司、医疗公司、CRO/CMO公司及国内领先的制药公司达成合作协议，协助其拓展海外市场与引进海外中高端人才。

除此之外，AF乐于帮助初创公司提供相关招聘策略咨询服务，助力中国本土企业、潜在新型力量的发展与壮大。

李艳（Jane LI）—联合创始人

12+年工作经验，其中9年专注于医药研发领域招聘经验，在该领域内积累了丰富的国内外高端人脉；

突出的业务能力和团队管理能力，5年间从资深顾问到稳定10+人团队，实现团队人均百万业绩；

对中国医药行业发展历史及趋势有非常深入和全面的了解；

多次参加ISAPA美国年会（新泽西/波士顿等），受邀做了两场科研从业者职业发展相关主题的演讲；

目前负责公司的战略制定和业务发展事宜。

孙宇聪（Jacky SUN）—联合创始人

拥有13年的招聘经验，并扎根在制药及医疗相关领域10年，对中国制药和医疗器械行业的大环境和技术前沿有着深刻的洞察力；

曾从无到有建设制药及医疗领域团队，此后以每年100%的利润增幅带领团队成长；

曾担任分公司负责人，擅长并深谙跨领域管理之道；

目前专注于制药及医疗相关领域高管类人才的招聘，并承担公司运营管理的职责。

Leading Total Talent Solutions Provider

Recruiting expert in healthcare industry of China

15,000+  Middle to senior - level management and technical positions fulfilled per year
60,000+  Temporary and outsourced positions fulfilled per year
1,500+  Professional recruitment consultants
80+  Offices across global markets
22  Years of successful operations
132  Outlets worldwide with global strategic partnerships
100  Employees focusing on the healthcare field

Recruitment position

- CSO Discovery head (biologics, Oncology)—Shanghai/Suzhou/Hangzhou/Nanjing/Chengdu, Pharma
- Head of Clinical Diagnostic/VP of the company—China, Star Pharma
- CTO(Biologics CMC,CAR-T)—Shanghai/Chengdu, local pharma
- Biologics CMC Director—Shanghai/Suzhou, Pre-IPO Pharma
- Bioprocess VP—Shanghai, Pre-IPO Pharma

For more information, please contact:
Blair Bu
18930475047
blairbu@chinacareer.com

Career International
The first A share-listed Chinese HR service enterprise
Stock code: 300662

Website: www.af-recruiting.com
Address: Shanghai, China (Head Office)
Tel: 021-22834800
Fax: 021-22893211
Email: China@af-recruiting.com

USA:
5 Walnut Hill Park, Suite 13, Woburn, USA 01801
Tel: +1 617 379 28 88
Fax: 617-379-2888
Email: US@af-recruiting.com
Luye Pharma (02186.HK), an affiliate of Luye Life Sciences Group, is a R&D driven pharmaceutical company with innovation and globalization as its two strategic focuses. Dedicated to R&D and manufacturing of innovative medications, the company is one of the first Chinese pharmaceutical companies to conduct clinical trials in major international markets. The company has state-of-the-art production facilities in Yantai, Beijing, Nanjing, Luzhou and Miesbach, R&D centers located in China, the U.S and Europe, as well as overseas branch offices in Hong Kong, Singapore and Malaysia with approximately 4,000 employees.

Luye Pharma focuses on four therapeutic areas: central nervous system, oncology, cardiovascular and metabolism. The company has a portfolio of over 30 products. The business of Luye Pharma covers global main pharmaceutical markets including China, the U.S, Europe, Australia, Japan and South Korean. Luye Pharma has established a professional R&D system of international standard, and reached international level in the area of new drug delivery system technologies such as microspheres, liposome and TDS. Currently, Luye Pharma has several investigational products under clinical trials in the U.S and Europe.

Kelun Pharmaceutical was founded in 1996, headquartered in Chengdu, China.
Over 100 subsidiaries, including Klus Pharma in New Jersey.
A top 10 Chinese pharmaceutical company with over 6 billion USD revenue in 2016.
Focusing on unmet medical needs involving cancer, liver disease, diabetes, cardiovascular disease, autoimmune disease, etc.
Programs include generics, new drug delivery systems, innovative small molecules and biologics.
Kelun-Biotech Biopharmaceutical Co. Ltd, a subsidiary of Kelun Pharmaceutical, was established in 2016, focusing on innovative small molecules and biologics.

Hui Wang, PhD
8 Clarke Drive, Suite 4, Cranbury, NJ 08512
Email: hui.wang@kluspharma.com
Simcere Pharmaceutical Group is a Chinese pharmaceutical company with 4500 employees. It is amongst the pioneering companies to develop and launch innovative drugs in China. Simcere is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease, as well as technology platforms in Cell Therapy and Artificial Intelligence. Simcere now has a significant global presence, including US and Europe.

Join us!

Simoon Record
Vaccine Clinical Study Expert in China

Founded in 2008, Beijing Simoon Record Pharma Information Consulting Co., Ltd. is a Contract Research Organization (CRO) focusing on biological products in clinical trial. Simoon Record’s core business includes clinical operation, on-site trial management for preventive biological product studies, providing end to end service for clinical trials process. The subsidiary Key Tech Statistic Technology is focused on clinical statistic and data management.

Core Competencies

- 25+ species of vaccine
- 90% CFDA inspection pass rate
- Successfully conducted 5+ efficacy studies with more than 10,000 subjects
- 90+ cooperated clinical study sites
- 50+ new developed clinical study sites
- 160,000+ subjects were enrolled
- Experience of 100+ vaccine clinical trials
- 12 provincial clinical study institutions
- Possessed over 50% market share of China vaccine clinical trials in 2017
- Most professional vaccine clinical study team of China
- Beijing high-tech enterprise
- Professional technical team of 200+ employees

Contact us: D405-406, Yuanyang International Center, Chaoyang District, Beijing, China
Tel: 86-10-87513865
Email: marin.huang@simoonrecord.com
For more information, please visit our official website: http://www.simoonrecord.com/
Global Platform. One Vision.

Small Molecule Drug R&D and Manufacturing
Biologics R&D and Manufacturing
Cell Therapy and Gene Therapy
Medical Device Testing
Genomics and Molecular Diagnostics

WuXi’s Vision
To become the most comprehensive capability and technology platform in the global pharmaceutical and healthcare industry to fulfill the dream that "every drug can be made and every disease can be treated".

Bristol-Myers Squibb
STUDY CONNECT
A NEW CLINICAL TRIAL EXPERIENCE
Learn about clinical trials, connect with other patients, and search for a clinical trial that may be the right fit for you or a loved one.

BMSClinicalTrialResearch.com
Leading insurance broker to the life sciences industry, from preclinical to commercialization. Gallagher provides comprehensive risk management advice and services to companies at every stage of development.

盖勒格风险顾问公司是全球最大的保险经纪公司之一。从临床到商业化的每个发展阶段，盖勒格为生命科学和制药公司提供全面的风险管理建议和服务。

ajg.com
The Largest Publicly Traded and a Leading Biopharma based in China with Growing Global Footprint

Overview

A Global Biopharmaceutical Company Founded in 1970  Listed on the Shanghai Stock Exchange since 2000

Market Capitalization\(^1\) $37bn

2017 Revenue $2.2bn  Annual Revenue Growth 25%

2017 Net Income $0.5bn  Net Income Margin 23%

Annual R&D Investment 13%

Novel Biologics & Small Molecules in Clinical Development 25

CFDA approved NMEs 2

ANDAs in U.S., EU and Japan 10

2017 Revenue $2.2bn  Annual Revenue Growth 25%

2017 Net Income $0.5bn  Net Income Margin 23%

Annual R&D Investment 13%

Novel Biologics & Small Molecules in Clinical Development 25

CFDA approved NMEs 2

ANDAs in U.S., EU and Japan 10

1. As of April 10, 2018.

Broad Capabilities in China and Globally

- 7 research centers worldwide, with > 2,100 dedicated researchers
- > 70 internally developed NMEs
- > 750 clinical experts leading >100 clinical trials worldwide
- Commercial-scale small molecule and biologics manufacturing facilities
- > 10,000 in house sales representatives covering >5,000 hospitals in China

Locations

China
- Beijing
- Chengdu
- Hongkong
- Lianyungang
- Nanjing
- Shanghai
- Suzhou

United States
- New Jersey
- Sydney
- Nagoya
- North Rhine-Westphalia

Australia

Japan

Germany

Financial Independence Planning is proud to support Sino-American Pharmaceutical Professionals Association of Greater Philadelphia on their 16th Annual Conference

“A sound plan should free up your time from worrying about money to enjoying all the things in life that are most important to you.”

FINANCIAL INDEPENDENCE PLANNING, LLC™

Approach Your Future With www.myFIPadvisor.com

Since 1995

Investment adviser representative and registered representative of, and securities and investment advisory services offered through Voya Financial Advisors, Inc. (member SIPC). FIP is not a subsidiary of nor controlled by Voya Financial Advisors.

The Process that Builds Confidence

35667976_0520D
Do you know where your antibodies are coming from?

Rockland is a frequently referenced antibody manufacturer and collaborates with leading organizations to develop high-quality antibodies and antibody based tools.

**Rockland is a name synonymous with reliability, specificity, and sensitivity.**

- Extensive line of antibodies and reagents
- Non-normalized antibodies for higher concentrations
- Multi-assay validated products
- Custom services available
- Trial size antibodies available
- USDA accredited animal facilities

orders@rockland-inc.com  www.rockland-inc.com
AbMax Biotechnology Co., LTD was incorporated in Beijing, China, in 2006. AbMax has 1200 m² research facility and 300 m² office space and now is a high-tech enterprise and training base for the national life science and technical personnel. AbMax has the world’s most advanced one-stop technology platform for antibodies and kits researching, which has the monoclonal antibody developed in an average of 46 days with a high success rate of 90%.

Address: 99Kechuang 14th Street, Building 18, Unit 2, Suite 208A, Beijing, China 101111  
Tel: 86-10-59755729 , 86-10-59755728  
Fax: 86-10-59755718  
Email: info@antibodychina.com  
Website: www.antibodychina.com

*Antigen Epitope Analysis & De-antigenicity of Protein/Antibody Drugs  
*ADA Assay Development  
*PK Assay Development  
*HCP Detection Kit Development  
*Mouse Monoclonal Antibody  
*Monkey Polyclonal Antibody  
*Antibody Drug Development

WE POWER ANTIBODY DISCOVERY

- Adagene was co-founded by two serial entrepreneurs, Peter Luo and Ge Li, to power antibody discovery in China for the world market.
- Adagene is showcasing the power of its proprietary Dynamic Precision Library (DPL) by advancing multiple innovative IO antibody therapeutics into clinical trials around the world.
- Adagene is a well-funded, privately held company. Having successfully raised over $85 million from established, international VC groups.
- Adagene is located in a leading biotech park, BioBay, in Suzhou, China.
- We are building a global and talented team with highly respected and regarded scientists. Adagene is looking for entrepreneurial and driven multidisciplinary talent to join our team.

FOR MORE INFORMATION, PLEASE VISIT WWW.ADAGENE.COM.
LEADERSHIP IN HEALTHCARE INVESTING

A fund dedicated to promoting innovative life science venture on a diversified basis:

- New Drug Development
- Genetic Engineering
- Immunotherapy
- Medical Device
- In Vitro Diagnosis

Alpha Bioventure is founded to promote the development needs of life sciences industry, including focusing on improving healthcare service facilities and intellectual property rights. Our staff have rich experience in the biomedical industry and also have cooperated with some well-known device companies and specialist consultancies. With mature venture capital (VC) ecosystem, we can make use of professional resource or technical knowledge to accelerate your projects.

Alpha Bioventure is recruiting investing projects and pharmaceutical experts. Join us!

www.alphabioventure.com
2200 SMITHTOWN AVE, RM 1 RONKONKOMA, NY 11779-7329, USA
Tel: 1-516-927-7606  Email: info@alphabioventure.com

ASTATECH

Catalog Products (>100,000 products, 85% in stock)
Custom Synthesis / Manufacture   GMP Compliance
20 years track record   400 dedicated employees

2525 Pearl Buck Road, Bristol, PA 19007
www.astatechinc.com  215-785-3197
成美律所由旅美华人律师创立，为客户提供高端国际并购、投资、知识产权（专利、商业机密等）法律服务；
成美律所拥有美国华人顶级商业和知识产权律师团队：3名合伙人获得美国著名法学院法律博士，在华尔街事务所累计执业数十年；
成美律师理解生命科学：2名合伙人获得化学、生物博士；
成美客户多来自生命科学、医药、医疗设备行业；
成美律师理解中美文化、商业以及法律惯例，娴熟处理中资赴美法律与合规问题。

联系我们：www.ambizlaw.com
1 Penn Plaza, Suite 2508, New York, New York

柳治平 合伙人 陈勇 合伙人
Tel: 212-547-6695 212-547-6694
zliu@ambizlaw.com ychen@ambizlaw.com
In pursuit of your success

Join Our Growing Biotech Team!

“Getting to work closely with patients is exciting and extremely humbling for me. Every day I learn more about how CSL is making a difference in patients’ lives. I’m exactly where I want to be.”

- Collins

Join Our Growing Biotech Team!

We’re looking for talented people like you to grow your career while contributing to the greater good. Visit www.cslbehring.com/careers

patient-focused
Frontage is a full service CRO that collaborates with pharmaceutical and biotech companies, helping them bring promising drug candidates to market.

We are committed to forging a partnership with our clients in order to provide real solutions to their drug development challenges.

Our experts in analytical testing, product development, DMPK, bioanalysis, clinical, and biometrics will work with you to turn services into solutions.

Partnership >
It’s how we turn services into solutions.
Metropolitan Acoustics is an acoustics and vibration consulting firm that specializes in lab vibration, sound and ultra-sonic monitoring, diagnostics and analysis.

Our monitoring system is wireless and cloud-based allowing users to experience real-time surveillance or view past data through an intuitive client portal.
成就自我，樂於助人，共創美好人生

這份銷售職業能讓您在激勵嘉勉的工作氛圍裏獲得高收入和成長的潛能，請與我們聯繫。

紐約人壽保險公司
Valley Forge General Office
595 E Swedesford Road, Suite 300
Wayne, PA 19087

江周小芬 Clara Kong
總經理 Managing Partner
484-595-2401
ckong@ft.newyorklife.com

EOE M/F/D/V/SO        SMRU1740589 (Exp.06/19/2019)      ©2017 New York Life Insurance Company, 51 Madison Avenue, NY, NY 10010

Phone: 1-516-927-7606
WeChat ID: DC15810168916
Email: info@protheragen.com
https://www.protheragen.com
2200 Smithtown Avenue, Room 1 Ronkonkoma, NY 11779-7329 USA

We welcome all project owners to contact us for further discussion and cooperation!

Incubate Your Drug Project With Protheragen
We offer one-stop solution for early-stage drug projects

- Investment
- R&D
- In/Out-Licensing
- Technology Transfer

Protheragen is an incubator of collaborative drug discovery research through alliances with various organizations. We focus on the licensing, incubation, and promotion of new drug programs. We adopt the VIC R&D model – V (risk investment), I (intellectual property), and C (CRO) – to make drug discovery activities most efficient by taking full advantages of each institution.
A global provider of Biological Reagents & Services

- Proteins: > 6000 Recombinant Proteins, world largest protein Bank
- Antibodies: >9000 Antibodies for various applications
- Genes: >200,000 Genes, cloned in Expression Vectors, ready to use
- CRO services: Antibody Generation, Protein Production & Drug Development

How to Order? order_us@sinobiological.com

Sino Biological US Inc.
1400 Liberty Ridge Drive,
Suite 101 Wayne, PA 19087

T: 215-583-7898
F: 267-657-0217
W: sinobiological.com

VITA SPES

STRONG & RELIABLE CLINICAL TRIALS CRO SERVICES
PHASE I, II, III, AND MORE...

Contact Info:
Daniel Qi, MD, PhD, Managing Director
Vita Spes, LLC
233 Mount Airy Road
Basking Ridge, NJ 07920
Tel: 609-259-4362
Email: daniel.qi@vita-spes.com
Kaitai Capital currently manages 6 billion RMB (~$800 million) for its VC business and 50 billion RMB (~$7 billion) for its PE business. Kaitai’s main areas of interest include biotech, healthcare services, agriculture, and TMT. Within biotech sector, Kaitai is particularly interested in cancer, immune diseases, eye diseases, bone/joint diseases, HBV infection, Gram negative infection, NASH, fibrosis, renal diseases. Kaitai has invested in nearly 20 biotech companies in China and the US. (For more information: www.ktcap.cn/)
WE SEQUENCE, YOU DISCOVER

From Biomarker discovery and validation to Companion Diagnostics, BGI is the Pharma Services Organization of choice for 18 of the top-20 Pharma companies.

**Pharma Services**
BGI's Experience and Network:
✓ Global partnership experience
✓ Quality and Regulatory compliance
✓ Access to patients in China
✓ Access to government and clinical resources in China
✓ Validated cancer panels

**Sequencing Services**
Global NGS Services:
✓ Genomics
✓ Transcriptomics
✓ Epigenomics
✓ Immune Repertoire
✓ Bioinformatics

To learn more about how BGI's experience can put your Drug Discovery projects in overdrive, come talk to us at our booth, or visit our web site [www.bgi.com](http://www.bgi.com)
Morgan Stanley

Morgan Stanley is proud to support

SAPA-GP

Irene Liu
Portfolio Manager
Financial Advisor
522 5th Avenue
New York, NY 10036
+1 212 296-0238
Irene.Liu@morganstanley.com
http://www.morganstanleyfa.com/irene.liu
NMLS# 1395620

Organizing Committee Members

David Cragin     Haifeng Cui     Li Cui     Han Dai     Patrick Deng
Rong Fan         Meizhen Feng    Yu Gao     Dennis Gross
Dan He           Xianhua Li      Yutai Li    Donghui Li    Pengbo Guo
Yin Liang        Xue Liang       Yang Liu    Yangsi Ou     Yufeng Li
Fang Shen        Bin Shi         Mengjie Si
Huaping Tang     Yeqing Tao      Dan Tian    Yongsuo Su    Chun Shao
Lu Wang          Kun Wang        Zhiyun Wen
Shuang Wu        Di Wu           Jun Xing    Hui Wang      Hao Sun
Li Yan           Jing Yang       Hanghang Zhang

Program Directors

Haifeng Cui     Jing Yang

Art Design and Brochure Editing

Pengbo Guo     Mengjie Si     Di Wu     Shuang Wu